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1. Introduction
A biomaterial is any material that comprises whole or part of a living structure or biomedi‐
cal device which performs, augments, or replaces a natural function to improve the quality
of life of the patients [1]. Over the past fifty years biomaterials has been developed as a sci‐
ence with various forms of implants/medical devices, and have been widely used to replace
and/or restore the function of traumatized or degenerated tissues or organs. As a life-saving
and life-improving option for countless patients, biomaterials have been paid more and
more attention during the last decade. Only in the United States, more than 13 million im‐
plant/medical devices implanted annually. As a result, the impact factor of the journal of
“Biomaterials” has boomed from 2.489 to 7.404 from the year 2001 to 2012.
The implant/medical device scope of biomaterials ranges from simple implants like intraoc‐
ular lenses (which restore sight to millions of cataract patients every year), sutures, wound
dressings, decellular matrices, bone plates, joint replacements to more complex materials
like biosensors, catheters, pacemakers, blood vessels, artificial heart (that provide both me‐
chanical and biological functions in a body), left ventricular assist devices and prosthetic ar‐
terial grafts. According to the resources and properties biomaterials can be assorted into
autografts, allografts, organic polymers, such as natural collagen, fibrin, chitosan, hyaluron‐
an, heparin, cellulose, and synthetic polyurethane (PU), polyester, metal, such as alumini‐
um, steel, titanium, inorganic salts, such as calcium phosphate, hydroxyapatite, and their
compounds or derivatives. There are more than one hundred different biomaterials which
have been applied in vivo. All biomaterials when implanted into a body initiate a host re‐
sponse that reflects the first steps of tissue repair. The host/biomaterial interactions which
follow implantation of any prosthesis or device are a series of complex events that have not
been well defined. Generally, host reactions following implantation of biomaterials include
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injury, blood–material interactions, provisional matrix formation, acute inflammation,
chronic inflammation, granulation tissue development, foreign body reaction, and fibrosis/
fibrous capsule development [2]. There are numerous types of host responses to a broad
spectrum of biomaterials.
When considering a biomaterial for implantation or medical use, the first and most impor‐
tant requirement is nontoxic, nonimmunogenic, chemically inert/active, and acceptable by
the human body. Biocompatible in most cases means that the biomaterials must not form
thrombi in the blood system, result in tumors in the surround tissues, or be immediately at‐
tacked, encapsulated, or rejected by the body [3]. According to the host responses to im‐
plantable biomaterials, there are many different kinds of biocompatibilities, including local
tissue responses, such as necrosis, repulsion, infection, inflammation, calcification, scar, cyst,
amalgamation, thrombus, tumor, cancer, and whole body responses, such as fever, toxicity,
circulation impediment, nerve anesthesia, malformation, etc. The overall biocompatibilities
including cyto-compatibility, hemo-compatibility, and tissue-compatibility, are often evalu‐
ated using histological sections, cell markers, and metabolite measurements. Sometimes,
polymers with similar chemical characteristics behave differently in certain situations. For
example, polyethylene and ultrahigh molecular weight polyethylene behave differently as
orthopedic biomaterials for knee and hip replacement [4]. Until present, most of the im‐
plantable biomaterials trigger acute or/and chronic inflammatory responses in the body.
These reactions can totally black a biomaterial and even lead to huge disasters or personal
misfortunes. Among the numerous types of host responses, early interactions between im‐
plants and inflammatory cells are probably mediated by a layer of host proteins on the bio‐
material surface. Franz and coworkers have described several typical host responses of
implantable biomaterials (Figure 1) [5]. This model can be used as a reference for evaluation
of an implantable biomaterial when it is implanted shortly in vivo.
In this chapter, I will focus on the in vivo host responses about twenty common used bioma‐
terials which cover nearly every tissue and organ in human body. Advanced biologic techni‐
ques have been employed in determining the mechanisms behind observed macroscopic or
microscopic responses. An understanding of the molecular and cellular events which occur
in response to implantable biomaterials may allow us to manipulate responses and design
more biocompatible, bioactive and functional biomaterials for clinical applications, such as
regenerative medicine and controlled releasing drugs.
2. Allografts
Allograft (also called homograft) is a tissue/organ graft from one individual to another of the
same species with a different genotype [6]. It has been successfully used in various medical
procedures for more than 150 years. Approximately 1500000 allografts are transplanted each
year for a variety of life-saving and life-enhancing surgeries. For example, skeletal grafts for
patients with bone defects from cancer or traffic accidents; cornea transplants to help restore
sight; heart valves to replace damaged heart tissues; skin grafts to save the lives of burn vic‐
tims, and tendon replacements to help people with more active lives [7].
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Figure 1. Immune response toward biomaterials. (A) Adsorption of blood proteins and activation of the coagulation cas‐
cade, complement and platelets result in the priming and activation of polymorphonuclear leukocytes (PMNs), monocytes
and resident macrophages. (B) Danger signals (alarmins) released from damaged tissue additionally prime the immune
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cells for enhanced function via pattern recognition receptor (PRR) engagement. (C) The acute inflammatory response is
dominated by the action of PMNs. PMNs secrete proteolytic enzymes and reactive oxygen species (ROS), corroding the bio‐
material surface. Interleukin (IL)-8 released from PMNs enhances PMN influx and priming. In the transition from acute to
chronic inflammation, PMNs stop secreting IL-8 in favor of cytokines promoting immigration and activation of monocytes
and macrophages. (D) Macrophages are the driving force of chronic inflammation. Constant release of inflammatory me‐
diators like tumor-nekrose-faktor alpha (TNFα), IL-6, and monocyte chemotactic protein (MCP)-1 results in permanent acti‐
vation of macrophages. Fusion-inducing stimuli like IL-4 and IL-13 promote the fusion of macrophages to foreign body
giant cells (FBGCs,) which form a highly degradative environment on the biomaterial surface. Furthermore, FBGC promote
extracellular matrix (ECM) remodeling and fibroblast activation resulting in excessive fibrosis and biomaterial encapsula‐
tion. (E) Macrophage-derived cytokines and pattern recognition receptor engagement activate dendritic cells (DCs) on the
biomaterial surface. Depending on the nature of the stimulus, DCs mature to either immunogenic or tolerogenic subtypes,
amplifying or suppressing the inflammatory response [5].
Compared with autografts which come from the same bodies and are only available in limit‐
ed amounts, allografts are more readily available and accompany with less risk and postop‐
erative morbidity. The healing times is therefore shorter and less painful for a patient with
no second surgical site is required (as there is when an autograft is utilised). Currently, the
use of allograft tissues is increasingly popular all over the world, with widespread orthopae‐
dic surgeons and debilitating musculoskeletal conditions. Nearly one tissue/organ donor
can save or improve the lives of up to 60 people. Especially, Musculoskeletal Transplant
Foundation, the world's largest tissue bank, provides allograft tissue and biologic solutions
for ligament reconstruction [8]. Meanwhile bone and soft tissue allografts from the Steri‐
Graft™ line has been in existence for over 13 years and has helped doctors and their patients
with over one hundred thousand successful transplantations. Before transplantation, a
blood sample from the donor is normally tested in case any infected diseases, such as hu‐
man immunodeficiency virus (HIV), Hepatitis, and Syphilis [9].
Specially, decellularized tissue/organ matrices derived from allografts have been used since
the 1940s to support tissue repair and replacement. Their popularity has grown sharply dur‐
ing the last decade with the advent of tissue engineering [10]. At present, decellularized tis‐
sues/organs have been successfully used in a variety of tissue/organ regenerative medicines.
The efficiency of cell removal from a tissue/organ is dependent on the origin of the tissue/
organ and the specific physical, chemical, and enzymatic methods that are used. Each of
these treatments affects the biochemical composition, tissue ultrastructure, and mechanical
behavior of the remaining extracellular matrix (ECM) scaffold, which in turn, affect the host
response to the material [11].
3. Collagen and gelatin
Collagen is one of the most prevalent proteins in the connective tissue of animals and consti‐
tutes approximately 25% of total body protein in vertebrates. It therefore is an important bi‐
omaterial in medical, dental, and pharmacological fields. After the immunogens in the
collagen molecules are dislodged, collagen has excellent biocompatibilities either in vitro or
in vivo. Collagen is capable of being cross-linked into solid or lattice-like gels. Resorbable
forms of collagen have been used to dress oral, skin or some of the other soft tissue wounds,
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for closure of graft and extraction sites, and to promote healing [12]. During in vivo implan‐
tation, collagen irritates slight inflammation accompanying with some scar tissues.
A collagen sponge obtained from Beijing Yierkang Biengineering Development Center Chi‐
na was implanted subcutaneously in rats for time periods up to 8 weeks (Figure 2) [13]. One
week after implantation, slight inflammation with some lymphocytes, myofibrils and fibro‐
blasts were observed. The appearance of myofibrils and fibroblasts indicated that scar tissue
was developed (Figure 2A). Two weeks after implantation, fibrous tissue was formed with
scattered macrophage and lymphocyte cells in the fibrous layer. Newly formed blood ves‐
sels appeared in the implant site while the collagen sponges were completely resorbed (Fig‐
ure 2B). Four weeks after implantation, the thin fiber layer had changed into wavelike scar
tissue and tightly connected with the surrounding muscles. Capillaries were evident in the
new fibrous scars (Figure 2C). Six weeks after implantation, scar tissue in the collagen sam‐
ples was mature (Figure 2D). Eight weeks after implantation, the wave-like scar tissue in the
collagen samples became thinner with some lipocytes and vacuoles (Figure 2E) [13].
Collagen compounds, such as collagen/chitosan, collagen/hyaluronan, have been investigat‐
ed extensively during the past several decades. The biocompatibilities of these compounds
depend largely on the incorporated constituents. For example, a corneal collagen cross-
linked with riboflavin and ultraviolet radiation-A has been used for keratoconus repair of a
29-year-old woman with some good results [14]. In some instances, it is more competing to
use a compound to improve the mechanical properties of the collagen based biomaterials.
For example, a porous implantable dexamethasone-loaded polylactide-co-glycolide (PLGA)
microspheres/collagen glucose sensors [15] and a mitomycin C (MMC) delivery system
(MMC-film), incorporating polylactide (PLA)–MMC nanoparticles in a composite film from
blends of collagen–chitosan–soybean phosphatidylcholine (SPC) with a mass ratio of 4:1:1
have been explored with no sign of internal infection and fibrous encapsulation in any ani‐
mals after 20 days of implantation [16].
Gelatin is a mixture of peptides/proteins produced by partial hydrolysis of collagen extract‐
ed from the skin, boiled crushed bones, connective tissues, organs and some intestines of an‐
imals such as domesticated cattle, chicken, horses hooves, and pigs [17]. Gelatin possesses a
better biocompatibility than its ancestry collagen. Alloimplants of bone matrix gelatin are ef‐
fective in the treatment of bone defects with a low risk of complication such as rejection or
infection [18]. Aqueous gelatin solution is an amorphous natural hydrogel in which cells can
be encapsulated, extruded and deposited at desired positions. Unlike collagen hydrogel, gel‐
atin hydrogel holds a special gelation property around 20℃. In Tsinghua University the au‐
thor’s own group, this property has been explored extensively for rapid prototyping (RP)
(or additive manufacturing) of three-dimensional (3D) complex geometrical structures with
computer-aided design channel models [19-24]. Until now, a hybrid hierarchical 3D con‐
struct consisting both synthetic polyurethane PU and natural cell/ gelatin-based hydrogel
with interconnected macro-channels has been produced via a double nozzle RP technique at
a low temperature (-28℃). These constructs have demonstrated excellent in vivo biocompa‐
tibilities [23,25]. This technique holds the potential to be widely used in the future complex
tissue/organ manufacturing areas.
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 Figure 2. Light-microscope evaluation of the tissue response to collagen sponges with hamatoxylin-eosin (HE) stain‐
ing: (A) 1 week after implantation; (B) 2 weeks after implantation; (C) 4 weeks after implantation; (D) 6 weeks after
implantation; (E) 8 weeks after implantation. The scale bar indicates a distance of 50μm in (A), (C), and (D), and a
25μm in (B) and (E) [13].
Combination of gelatin microspheres/scaffolds with other biomaterials, such as collagen, al‐
ginate, chitosan, hyaluronan, and fibrin has also been explored extensively. For example, a
gelatin microsphere containing basic fibroblast growth factor and preadipocytes, is essential
to achieve a engineered fat tissue [26]. A PLGA microparticles containing an anticancer
agent paclitaxel was formulated for the treatment of lung cancers [27]. Gelatin hydrogel in‐
corporating hepatocyte growth factor induced angiogenic change around the implanted hy‐
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drogel [28]. A silk fibroin/gelatin composite scaffold was implanted into subcutaneous
pockets on male Sprague-Dawley rats with a slight inflammation reaction. By day 30, the
scaffold had been completely infiltrated and organized by fibroblasts and inflamed cells.
The greater the gelatin concentration in the scaffold, the faster the degradation rate [29].
4. Fibrin
Fibrin (also called Factor Ia) is a fibrous, non-globular protein involved in the clotting of
blood. It is formed from fibrinogen by the protease thrombin, and is then polymerised to
form a hemostatic plug or clot (in conjunction with platelets) over a wound site [30]. The clot
fibrin can be naturally degraded by proteolytic enzymes from the fibrinolytic system, such
as plasmin [31,32]. In vivo, fibrin(ogen) plays an important role in hemostasis, inflammation,
signal transduction, platelet activation, wound healing, osteoinductive and angiogenesis
[33-36]. The food and drug administration (FDA) in American has approved commercially
made fibrin sealants in 1998 [37].
During the last decade, autologous fibrin-based matrices have demonstrated great potential as
being used as tissue engineered replacements, such as heart valves [38-40], cartilages [41], and
blood vessels [42]. Immunohistochemistry and ECM assay demonstrated that the fibrin scaf‐
folds can be completely absorbed in vivo in about 3 months with low granulomatous inflamma‐
tion (Figure 3) [43-46]. Farhat and coworkers have evaluated whether a fibrin glue spray
technique enhances cell seeded acellular matrix (ACM) repopulation in a porcine bladder mod‐
el. The in vivo central fibrosis results indicated that while fibrin glue enhanced cellular organiza‐
tion on ACM in vitro, factors supporting seeded cell survival are lacking [47].
On the other hand, spatio-temporal controlled delivery of bioactive molecules within fibrin
has been expanded rapidly. Various states of fibrin, such as scaffold, sheets, microparticles
and fibrin-coated drug particles have been used as drug delivery systems [48,49]. Growth
factors, such as vascular endothelial growth factor (VEGF) and transforming growth factor-
β (TGF-β) can easily bind to the fibrin molecules and be controlled released subsequently by
diffusion [50-56]. In the future, autologous fibrin may play an important role in customized
clinical applications, such as anti-immune drug delivery systems and human tissue/organ
constructions to avoid any negative host reactions [57].
5. Dextran and its derivatives
Dextran, a high-molecular-weight polymer of d-glucose, formed by sucrose enzymes on the
cell surface of certain lactic acid bacteria in the mouth adhere to the tooth surfaces and pro‐
duce dental plaque. Uniform molecular weight dextrans (named for their average molecular
weight) from Leuconostoc mesenteroides with specific preparations has been used for over
50 years in plasma volume expansion, thrombosis prophylaxis, peripheral blood flow en‐
hancement and for the rheological improvement of, for instance, artificial tears [30,58]. Dex‐
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trans with an average molecular weight of 1000 to 2 million g/mol are commercially
available for research purposes [59]. Two preparations of dextran with lower fractions
(40000 and 70000 g/mol) are suitable for nontoxic clinical use [60]. However, high fractions
of dextrans can produce erythrocyte aggregation, impaired microcirculation, and a clinical
picture akin to shock and certain other diseases.
Figure 3. Eleven-day Masson’s trichrome (MT) staining sections of a fibrin scaffold. (A) Untreated defects and (B) de‐
fects containing empty scaffolds were filled with new bone tissue. However, no reparative bone was observed in the
center of defects containing (C) scaffolds filled with fibrin (low T) and (D) scaffolds filled with fibrin (high T). (Inset)
Patches of multinucleated giant cells (striped arrow) were observed at the scaffold interface in all scaffold-containing
groups. Black arrows point to areas occupied by the scaffold, whereas white arrows point to the advancing bone
front. Field width 5.2 mm, inset field width 0.2 mm [46].
During 1990-1994, extensive toxicologic evaluations indicate that small-volume infusions of
7.5% NaCl/6% dextran 70 (HSD) at the proposed therapeutic dose of 4 mL/kg, present little
risk as implantable biomaterials [61,62]. Dextran hydrogels have offered good opportunities
as protein delivery systems or tissue engineering scaffolds because of an inherent biocom‐
patibility [63]. The hydrophilic, soft and rubbery properties of the dextran hydrogels ensure
minimal tissue irritation and a low tendency of cells and proteins to adhere to the hydrogel
surface [59]. Althogh dextran itself is not toxic, some of the methods used for crosslinking
the polymer may result in toxic byproducts. For example, the toxicity of dialdehyde cross‐
linked dextran/gelatin hydrogel can be detected in fibroblast and endothelial cell cultures.
Subcutaneous implantation studies in mice showed that the foreign body reaction seen
around the implanted hydrogel samples was moderate and became minimal upon increas‐
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ing implantation time [64]. A methacrylate-derivatized dextran hydrogel also shows good in
vitro biocompatibilities [65].
More recently another effect of dextran, namely that of antithrombogenesis, has been recog‐
nized [66]. Dextran sulfate, a dextran derivative, its effects on coagulation has already been
proven [67]. It has been reported that dextran sulfate has been found to activate the poly‐
merization of fibrin monomer, ATIII, conversion of prekallikrein to kallikreinand fibrinoly‐
sis. Kallikrein, the conversion of fibrinogen to fibrin appears to be inhibited by dextran
sulfate. These effects are, inter alia, concentration dependent [67,68]. Meanwhile, a dextran
sulphate sodium model of colitis has demonstrated several correlations of this biomaterial
with human inflammatory bowel disease [69]. Furthermore, a lauric acid modified dextran-
agmatine bioconjugate (Dex-L-Agm) was prepared by 1,1'-carbonyldiimidazole activation
and the nucleophilic reaction between tosyl of tosylated dextran and primary amine of ag‐
matine was found to be highly cytocompatible without causing hemolysis and red blood cell
aggregation [70].
6. Hyaluronan
Hyaluronan (also called hyaluronic acid or hyaluronate, HA) is a natural anionic, viscoelas‐
tic and hygroscopic glycosaminoglycan, discovered in 1934, by Karl Meyer and his assistant,
John Palmer in the vitreous of bovine eyes [71]. As one of the chief components of the ECM,
hyaluronan distributes widely throughout connective, epithelial, and neural tissues. It is
unique among glycosaminoglycans in that it is nonsulfated, forms in the plasma membrane
instead of the Golgi, and can be very large in molecular weight (often reaching the millions)
[72]. HA plays several important organizational roles in the ECM by binding with cells and
other protein components through specific and nonspecific interactions [73] and is responsi‐
ble for various functions within the ECM such as cell growth, proliferation, differentiation,
migration [74], and even some malignant tumors [76].
Basically hyaluronan is a highly non-toxic, non-antigenic and non-immunogenic polysac‐
charide, owing to its high structural homology across species,  and poor interaction with
blood  components  [77,78].  The  FDA  in  American  has  approved  the  use  of  hyaluronic
acid for certain eye surgeries,  such as cataract  removal,  corneal transplantation,  and de‐
tached  retina  [79].  People  take  hyaluronic  acid  for  various  joint  disorders  (lubricant
agents),  lip fillers,  "youth fountains”,  and even wound healing catalysts [80].  Nowadays
various hyaluronan hydrogels have been used to delivery drugs and cell  growth factors
[81,82].  There  are  some  evidence  show  that  fragmented  hyaluronan  stimulates  the  ex‐
pression of inflammatory genes by a variety of immune cells at the injury site. With the
protein-bonding  abilities,  hyaluronan  fragments  signal  through  both  Toll-like  receptor
(TLR)  4  and  TLR2  as  well  as  CD44  to  stimulate  inflammatory  genes  in  inflammatory
cells.  Hyaluronan  presents  on  the  epithelial  cell  surface  can  provide  protection  against
tissue  damage  from  the  environment  by  interacting  with  TLR2  and  TLR4  [83-85].  It  is
well  known that  accumulation  and  turnover  of  ECM components  are  the  hallmarks  of
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tissue  injury.  Current  model  of  hyaluronic  acid  appear  in  the  early  stages  of  wound
healing is to physically make room for white blood cells, which mediate the immune re‐
sponse  and  at  least  in  part,  reduce  collagen  deposition  and  therefore  lead  to  reduced
scarring [86].  This hypothesis is  in agreement with the research of West and coworkers,
who have showed that in adult and late gestation fetal wound healing process, removal
of HA results in fibrotic scarring [87].
HA can be modified through several  different  ways,  such as chemically esterify its  car‐
boxylic  groups with some types of  alcohol.  The physico-chemical  properties  of  the new
biopolymers allow the preparation of many biomaterials with different biocompatibilities
for various medical applications [88].  Shen and coworkers implanted hyaluronan hydro‐
gel  and  periodate  oxidated  hyaluronan  hydrogel  in  ischemic  myocardium  and  found
rapid degradation rates,  low quantity  of  inflammation-mediating cells,  thin fibrous cap‐
sules  with dense blood vessels  around the hydrogels  at  week 2 [89].  Praveen and cow‐
orkers  used  HA/polyvinyl  alcohol  (PVA)  coating  membrane  to  minimize  the  problems
related to protein deposition and fibrous tissue formation on an implanted glucose sen‐
sor [90].  HA hydrogels modified with laminin could support cell  infiltration, angiogene‐
sis,  and simultaneously inhibit  the formation of glial scar after being implanted into the
lesion  of  the  cortex  [91].  Compared  with  pure  gelatin  hydrogen,  HA/gelatin  composite
has  a  better  compatibility  and contiguity  with the surrounding brain tissue with no in‐
flammatory  reaction  and  fibrous  encapsulation  [92].  Intravitreal  implants  of  hyaluronic
acid  esters  represent  useful  biocompatible  and  biodegradable  properties  for  a  potential
drug delivery system in the treatment of posterior segment ocular diseases [93]. A cross-
linked  HA hydrogel  that  contained  a  covalently  bound derivative  of  the  anti-prolifera‐
tive  drug MMC was  synthesized and evaluated in  vitro  and in  vivo.  This  hydrogel  has
strong  potential  as  anti-fibrotic  barriers  for  the  prevention  of  post-surgical  adhesions
[94]. Two injectable thiolated HA derivatives were coupled to four alpha, beta-unsaturat‐
ed ester and amide derivatives of poly(ethylene glycol) (PEG) 3400 and were found that
the encapsulated cells can retained their original fibroblast phenotype and secreted ECM
in vivo [95].  A fibrin/HA composite gel  with autologous chondrocytes has been synthe‐
sized for tracheal reconstruction. Histologically, the grafts showed no signs of inflamma‐
tory reaction and were covered with ciliated epithelium [96].
7. Heparin
Heparin (from Ancient Greek ηπαρ (hepar),  liver),  a highly sulfated glycosaminoglycan,
is widely used as an injectable anticoagulant, and has the highest negative charge densi‐
ty  of  any known biological  molecule  [97].  Heparins  are  involved in  different  pathways
of the coagulation cascade with anticoagulant, antithrombotic,  profibrinolytic,  anti-aggre‐
gative,  as  well  as  anti-inflammatory effects  [98].  As stated in the fibrin section,  the pri‐
mary anticoagulant  effect  of  heparin is  through the suppression of  thrombin-dependent
amplification of the coagulation cascade, and inhibition of thrombin-mediated conversion
of fibrinogen to fibrin [99].
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Heparin holds the ability to relieve pain, inhibit clotting and inflammation, restore blood
flow, enhance healing, and can be a useful addition to a range of available treatments for
burn wounds [100]. Unfractioned heparin exhibits a broad spectrum of immunomodulating
and anti-inflammatory properties, by inhibiting the recruitment of neutrophils and reducing
pro-inflammatory cytokines in the treatment of inflammatory bowel disease [101]. Low-mo‐
lecular-weight heparin can reduce or prevent development of signs/symptoms associated
with post-thrombotic syndrome [102]. Heparin has been widely used to form an inner anti‐
coagulant surface on various experimental and medical devices such as membranes
[103,104], tubes and renal dialysis machines [105,106].
Although heparin is used principally in medicine for anticoagulation, its true physiological
role in the body remains unclear. Blood anti-coagulation is usually achieved by heparan sul‐
fate proteoglycans which derive from endothelial cells stored within the secretory granules
of mast cells and only released into the vasculature at sites of tissue injury [107]. Rather than
anticoagulation, the main role of heparin may be defense at such sites against invading bac‐
teria and other foreign materials [108]. A thiol-modified heparin in the Extracel-HP® mimics
heparan sulfate proteoglycans also normally presents in the ECM and regulates the in vivo
growth factor release for a functional microvessel network development [109]. A well-
known adverse effect of heparin therapy is thrombocytopenia, a serious, immune system–
mediated complication with significant mortality (Figure 4) [110-112].
8. Alginate
Alginate, is a salt of alginic acid ( medical-dictionary.thefreedictionary.com), and an anionic
polysaccharide distributed widely in the cell walls of brown algae, where it, through bind‐
ing water, forms a viscous gum (Wikipedia, the free encyclopedia). Sodium alginate (com‐
posed of mannuronic and guluronic (G) dimmers) is a biocompatible and biodegradable
polymer, and has been widely used in cell encapsulation technology, though the biocompat‐
ibility of the alginates in relation to their composition is a matter of debate [113]. In the mol‐
ecules of sodium alginate the primary block guluronic acid contains available carboxylic
acid groups that allow the alginate to be reversibly crosslinked by divalent cations, such as
Ca+2 and Mg+2, to form a relatively stable hydrogel [114,115]. Clinically, water-soluble algi‐
nates are useful as materials for dental impressions. Calcium alginates have been widely
used as a base material to encapsulate glucose-sensing pancreatic islets that secrete insulin
into the lymphatic system to reverse the effects of insulin-dependent diabetics [116]. Some
investigators have utilized alginates to promote the viability of encapsulated cells [117]. Al‐
ginate-poly-L-lysine-alginate (APA) microcapsules continue to be the most widely studied
device for the immuno-protection of transplanted therapeutic cells [118]. Alginate-chitosan-
alginate (ACA) microcapsules have been developed as a device for the transplantation of
living cells with protein adsorption onto the surface of microcapsules immediately upon im‐
plantation [119].
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Figure 4. Model of pathogenesis of heparin-induced thrombocytopenia (HIT). Heparin binds with Platelet factor 4
(PF4), which exposes neoepitopes on PF4 and leads to antibody production (1). Heparin-PF4-IgG immune complexes
form (2), and IgG in multimolecular complex triggers platelet activation via binding to Fc receptors (3). Activated pla‐
telet releases additional PF4 (4a) and prothrombotic platelet microparticles (4b). Thrombotic risk is further promoted
by binding of PF4 to heparin-like molecules on endothelial cells (EC), contributing to immune system–mediated endo‐
thelial damage (5) [112].
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9. Chitin, chitosan and their derivatives
Chitosan is a naturally occurring linear polysaccharide, consisting of glucosamine and N-
acetyl-glucosamine,  normally  made  of  deacetylated  chitin  which  is  the  structural  poly‐
mer found in the shells of crabs and shrimp (lobster,  squid, some yeast and mould), by
N-deacetylation using strong alkali [120]. More than 40 years have lapsed since this bio‐
material  had  aroused  the  interest  of  the  scientific  community  around the  world  for  its
potential biomedical applications [121]. Until now chitosan possess a number of commer‐
cial  and biomedical  applications  in  wound dressing,  drug delivery and tissue engineer‐
ing.  For  example,  chitosan  based  scaffold  biomaterials  have  demonstrated  versatile
properties  to  promote  the  epithelial  and  soft  tissue  regeneration  in  the  body  [122,123].
Chitosan patches in various sizes that have been cleared by the FDA are a topical hemo‐
stat  for  moderating  severe  bleeding.  Nevertheless,  an  obvious  disadvantage  of  this  im‐
plantable,  absorbable  biomaterial  is  that  chitosan  initiates  serious  host  inflammation
reactions (Figure 5)  [13,124].  Additionally,  chitosan is  bioadhesive and has the ability to
transiently  open  tight  junctions  in  the  nasal  epithelia,  thereby  permitting  drugs  to  dif‐
fuse  through  this  barrier.  Advantages  of  this  nasal  route  of  administration  include:  a
higher permeability  of  the nasal  mucosa than in the gastrointestinal  tract;  a  low degree
of pre-systemic metabolism; and a high level of patient compliance, compared to injecta‐
ble systems [125].
It  is  very  interesting  that  when  the  number  of  N-acetyl-glucosamine  units  in  a  chitin/
chitosan mixture is  higher than 50%, the biopolymer is  termed chitin.  50% deacetylated
chitosan  has  a  less  inflammation  reaction  than  the  others  when  they  are  implanted  in
vivo  [126].  Cross-linking  of  chitosan  membrane  using  genipin  and some other  chemical
agents can increase the membrane’s ultimate tensile strength but significantly reduced its
strain-at-fracture and swelling ratio [127]. In the author’s own group, an ammonia treat‐
ed  chitosan  sponge  was  implanted  subcutaneously  in  rats  for  8  weeks  (Figure  5).  One
week after implantation,  the chitosan sponges were entirely retained and wrapped with
a layer of purulent cells.  The purulent cells  had infiltrated the outside chitosan sponges
(Figure  5A).  Two  weeks  after  implantation,  the  encapsulated  purulent  layer  was  en‐
larged at the periphery of chitosan sponges. More acute inflammatory cells had infiltrat‐
ed  the  chitosan  sponges  and  there  was  no  sign  of  biodegradation  of  the  chitosan
sponges  (Figure  5B).  Four  weeks  after  implantation,  the  chitosan  sponges  still  main‐
tained their  porous structure.  A much thicker purulent layer and more acute inflamma‐
tory  cells  were  found  around  or  in  the  chitosan  sponges  (Figure  5C).  Six  weeks  after
implantation, most of the chitosan still maintained their scaffold integrity with numerous
interspersed purulent  cells.  Some purulent  cells  even formed large channels  throughout
the  chitosan  sponges  (Figure  5D).  Eight  weeks  after  implantation,  purulent  cell  infiltra‐
tions  had  further  increased  in  the  chitosan  sponges.  Some  collapsed  matrix  structures
were  detected  at  the  outer  margins  of  the  implants  and  more  channel  structures  were
found between the remnants of chitosan lamellae (Figure 5E).
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 Figure 5. Light-microscope evaluation of the tissue response to chitosan sponges with HE staining: (A) 1 week after
implantation; (B) 2 weeks after implantation; (C) 4 weeks after implantation; (D) 6 weeks after implantation; (E) 8
weeks after implantation. The scale bar indicates a distance of 50 μm in (A), (C), and (D), and a 25 μm in (B) and (E)
[13].
Also in this author’s own group, a series of bone repair materials were fabricated by adding
three chitosan derivatives, such as phosphorylated chitin (P-chitin), phosphorylated chito‐
san (P-chitosan), and disodium (1→4)-2-deoxy-2-sulfoamino-β-D-glucopyranuronan (S-chi‐
tosan) into two kinds of biodegradable calcium phosphate cements (CPCs). All the chitosan
derivatives can greatly improve the mechanical properties and reduce the biodegradation
rates of the CPCs. At least six totally different tissue responses were detected when the im‐
plants were examined in tibial and radial defects of rabbits. Large bone defect (9 mm in
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length for radii and 3 mm in depth and diameter for tibias) repair in rabbits with the P-chi‐
tosan incorporated CPCs exhibits excellent tissue compatibilities with no any adverse or
negative effects, such as fibrous encapsulation, osteolysis, hyperplasia, and inflammation,
no matter the concentrations of P-chitosan is high or low (Figure 6) [128,129]. Tissue re‐
sponses to P-chitin are highly sensitive (Figure 7) [130,131]. Three different bone formation
types in the resorption lacuna of the P-chitin incorporated CPCs due to the P-chitin concen‐
trations were found during the 22 weeks implantation. The first is that with low P-chitin
content trabeculae formed directly from the implant (Figure 7A). The second is that with
middle P-chitin content cartilages formed from the outside of fibers before they turned into
trabeculae (Figure 7B, 7C). The third is that with high P-chitin content callous formed from
the outside of fibers before they turned into trabeculae (Figure 7D, 7E). P-chitin content has
a negative relationship with the biodegradation rate of the cements. However, the degrada‐
tion rates are compatible with the ingrowth of trabeculae. A mild foreign-body reaction in
the high P-chitin content sample during the first three time spans did not impair its place‐
ment by a newly formed bone. The generally properties of these biomaterials have met the
main requirements for bone repair (Figure 7) [130,131]. Different from the above mentioned
bone repair types, tissue responses to water-soluble S-chitosan, prepared from chitin by suc‐
cessive N-deacetylation, specific carboxylation at C-6 and sulfonation, was rather obtuse. No
inflammation or other negative response was found in the S-chitosan containing samples (S-
CPCs). After 4 weeks implantation, newly formed trabeculae contacted with the implant di‐
rectly in the lower S-chitosan sample, while a thin layer of fibers formed between the newly
formed bone and the implant in the higher S-chitosan samples [132,133]. These results indi‐
cate that the concentrations and functional groups in a linear polysaccharide play a key role
in determining the ultimate biocompatibilities of an implantable biomaterial. In addition, as
a derivative of chitin, chitosan initiates blood coagulation while S-chitosan inhibits blood co‐
agulation when they are used as hemo-contact biomaterials.
Recently, chitosan and its derivatives have been widely used in skin wound, burn and dis‐
ease treatments. For instance, a chitosan-gelatin-hyaluronic acid scaffold was found flexible
with good mechanical properties when it was used as artificial skin substitutes [134]. A bac‐
terial cellulose synthesized by Acetobacter xylinum and modified by chitosan was found to
be optimal in providing wound dresses with a moist environment for wound healing [135].
When an artificial chitosan skin regenerating template was implanted subcutaneously it
showed a similar inflammatory pattern as Integra, a two-layer skin regeneration system,
constructed of a matrix of crosslinked fibers [136,137].
With the combination with other natural polymers, such as collagen, gelatin, hyaluronan, fi‐
brin, the strong host inflammation reactions of chitosan can be reduced to a certain degree.
It was found that a bioactive glass-chitosan composite containing 17% (wt%) chitosan pro‐
duced by a freeze-drying process and implanted in the femoral condyl of an ovariectomised
rat can promote a highly significant bioactive and osteoinductive property [138-140]. The ul‐
timate biocompatibility of a chitosan compound depends largely on the ratio of the different
components. Host tissues, such as smooth muscle and hepatic tissue have a similar response
to the chitosan containing collagen/chitosan mixtures [141]. A collagen/chitosan matrix
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crosslinked by agent 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide in a N-hydroxysucci‐
nimide and 2-morpholinoethane sulfonic acid buffer system has exhibited improved blood
and cell compatibilities than the pure chitosan samples [142,143].
 
Figure 6. Tissue responses to the P-chitosan incorporated CPC specimen at different time points with MT staining. (A)
1 week after implantation in the high P-chitosan content (0.12 g/mL) sample with very little hematoma. (B) 4 weeks
after implantation in the high P-chitosan content (0.12 g/mL) sample newly formed woven bone clearly appeared
with tightly bonding between the implant and host bone. No macrophage was found around the implant. The im‐
plant was directly changed into new trabeculae after degradation. (C) 12 weeks after implantation newly formed long
bone in the low P-chitosan content (0.02 g/mL) sample. (D) 12 weeks after implantation newly formed long bone in
the middle P-chitosan content (0.07 g/mL) sample. (E) 12 weeks after implantation newly formed long bone in the
high P-chitosan content (0.12 g/mL) sample. Trabeculae formed after the implant was gobbled up (infiltrated) by
body fluid. Clear evidence of remodeling around the implant surface was displayed. (F) 22 weeks after implantation
the newly formed dense trabeculae in the high P-chitosan content (0.12 g/mL) sample [129].
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 Figure 7. Tissue responses to the P-chitin incorporated CPC specimen 4 weeks after implantation. (A) P-chitin: 0.02
g/mL with MT staining. Magnification ×100. (B) P-chitin: 0.08 g/mL with MT staining. Magnification ×40. (C) A magni‐
fication of (B) with MT staining. Magnification ×400. (D) P-chitin: 0.14 g/mL with MT staining. Magnification ×40. (E) A
magnification of (D) with HE staining. Magnification ×400 [131].
Current advances in some drug delivery systems make it possible to improve the therapeu‐
tic efficacy and minimized the side effects associated with toxicity of the drug. Chitosan has
shown promise in the development of non-parenteral delivery systems for challenging
drugs. For example, a 5-Fluorouracil (5-FU) loaded scaffold composed of chitosan fibers
were prepared by a modified wet spinning technique [144]. Thermosensitive hydrogel com‐
posed of chitosan and glycerophosphate is proposed to be the potential candidate of in situ
gel-forming implant for long-term drug delivery [145]. However, unpredictable body re‐
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sponses to the chitosan systems as stated above can complicate their applications to some
degree. The composite chitosan-collagen-soybean phosphatidylcholine film impregnated
with MMC-PLA-nanoparticles for treatment of hepatocellular carcinoma in mice has exhib‐
ited some special characteristics compared with pure chitosan delivery systems. In vivo, the
growth of the tumors were inhibited considerably and dose-dependently by the MMC-film
(P<0.05) with no any signs of vice reactions, such as inflammation, infection, and fibrous en‐
capsulation after 20d of implantation [16,146,147]. Thus a careful balance between the im‐
mune reaction and drug effectiveness is needed when a chitosan pertaining template is used
for biomedical applications.
10. Polyglycolide (PGA), Polylactide (PLA) and poly(Lactic-co-Glycolic
Acid) (PLGA)
Polyglycolide also named polyglycolic acid (PGA) is a biodegradable, thermoplastic poly‐
mer and the simplest linear, aliphatic polyester which contains the ester functional group in
it’s main chain [148]. It can be prepared starting from glycolic acid by means of polyconden‐
sation or ring-opening polymerization. PGA has been known since 1954 as a tough fiber-
forming polymer. Owing to its hydrolytic instability, its use has initially been limited [149].
In vivo, PGA initiates a marked host reaction around the implantations. This leads to the de‐
velopment of a foreign body response that comprises an initial acute inflammatory phase
and a subsequent chronic inflammatory phase. For example, when a synthetic PGA scaffold
seeding with adult-derived or somatic lung progenitor cells from mammalian lung tissue
was implanted in an immunocompetent host, a serious foreign body response totally altered
the integrity of the developing lung tissue [150].
Polylactic acid or polylactide (PLA) is another thermoplastic aliphatic polyester derived
from renewable resources, such as corn starch, tapioca products, and sugarcanes [30]. A
poly(L-lactide) (PLLA) coil stent has ever been implanted in pigs with no stent thrombosis
and late restenosis [151]. However, PLA, as well as PLLA, and poly(D,L-lactide) (PDLA), in‐
duces a strong inflammatory response when they are implanted in the body due to their
acidic products [152]. Aframian and coworkers implanted tubular PLLA, PGA coated with
PLLA (PGA/PLLA), or nothing (sham-operated controls) in Balb/c mice either beneath the
skin on the back, and found that inflammatory reactions were shorter and without epithe‐
lioid and giant cells in the sham-operated controls. Tissue responses to PLLA and PGA/
PLLA scaffolds are generally similar in areas subjacent to skin in the back and oral cavity.
Biodegradation proceeded more slowly with the PLLA tubules than with the PGA/PLLA tu‐
bules. No significant changes in clinical chemistry and hematology were seen due to the im‐
plantation of tubular scaffolds. [153]. It was reported that, after the PLLA segments were
swallowed in vivo by phagocytes, cell damage and cell death were obvious. The highest
numbers of necrotic cells were observed on day 2 [154]. These reactions can result in an un‐
expected risk for patients and have strongly limited in clinical applications of this kind of
biomaterials.
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To date, numerous strategies have been investigated to overcome body reactions induced by
this kind of biomedical devices [155]. As a result, most of the PLA, PLLA, and PDLA have
been used as a composite or compound with some other biomaterials. For example, a PLLA
and poly(ethylene oxide) (PEO) blend has been prepared by mechanical mixture and fusion
of homopolymers [156]. A biodegradable star-shaped 8 arms PEG-b-PLLA block copolymer
was synthesized by Nagahama and coworkers to create a novel implantable soft material
with drastically lowered crystallinity, increased swelling ability, and desirable mechanical
properties [157,158].
Currently PGA, PLA and their copolymers, such as poly(lactide-co-caprolactone) (PLCA),
poly(glycolide-co-caprolactone) (PGC), and poly (glycolide-co-trimethylene carbonate) are
widely used as biomaterials for the synthesis of absorbable sutures and tissue engineering
scaffolds in the biomedical field [159,160]. For example, a resorbable PLGA bone fixation im‐
planted in craniofacial patients in 1996 resulted in 0.2 percent significant infectious compli‐
cations, 0.3 percent device instability, and 0.7 percent self-limiting local foreign-body
reactions [161]. As long-term implants, the toxicity of the accumulated acidate products
made the situations even worse [162]. Until the present, most of the implanted PGA, PLA
and PLGA related biomaterials still encounter an immune tissue response due to tissue trau‐
ma during implantation and the presence of foreign body reactions [163]. Surface coating
has become one of the research hot points for the implantable devices with poor biocompati‐
bilities. For instance, the biocompatibilities of some artificial polymer devices, such as heart
valves, stents and vascular prosthesis that come into contact with bodily tissues or fluids
particularly blood, have been improved by Venkatraman and coworkers with endotheliali‐
zation surface layers [164,165].
Similarly, when a polyvinyl acetate (PVA)/PLGA microsphere was implanted into the sub‐
cutaneous tissue of rats, acute inflammation with neutrophils was found at day 3. Chronic
inflammation with multinucleate giant cells, fibrosis, and mixed inflammatory cells was
found at day 30. Mineralization around the implant was found at day 60 [166]. On the con‐
trary, a dexamethasone/PLGA microsphere system can suppress the inflammation reaction
by a fast releasing of dexamethasone [167]. A highly monodisperse and smooth PLGA-pacli‐
taxel microspheres against malignant brain tumors were fabricated using an electrohydro‐
dynamic atomization (EHDA) process [168]. In addition, PLA, PGA and PLGA can be
tailored to meet mechanical performance and resorption rates required for applications
ranging from non-structural drug delivery applications, nanoparticles (nanofibers), to re‐
sorbable screws and anchors [169,170].
11. Polycaprolactone (PCL)
Polycaprolactone (PCL) is a biodegradable polyester with a low melting point of around
60°C and a glass transition temperature of about −60°C. It is commonly used as an additive
for resins or starch to improve their processing characteristics, lower their costs, and change
their properties (e.g. impact resistance), or as a plasticizer in the manufacture of special pol‐
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ymers (e.g. Pus) [30]. PCL has been approved by the FDA for specific applications, such as a
drug delivery devices, sutures, or adhesion barriers. It has been widely used as a scaffold
material for tissue engineering with mismatched mechanical properties and slow degrada‐
tion rate [171,172]. In rats the in vivo degradation of PCL is about 3 years [173].
Various categories of drugs have been encapsulated in PCL, in microsphere, nanosphere or
bulk states, for targeted drug delivery and for controlled drug release [174-176]. For exam‐
ple, a PCL scaffold modified by grafting nerve growth factor (NGF) and Tirofiban (TF) has
been used as nerve conduits to promote the regeneration of sciatic nerves [177]. Low molec‐
ular weight PCL pieces can be ingested and digested ultimately by phagocyte and giant cell
without any cumulate vice-products (Figure 8) [178-180].
Figure 8. Micrographs illustrating extracellular degradation of biomaterials by macrophage fused multinuclear giant
cells. (A) A foreign body giant cell (FBGC) engulfed a fragment of poly(epsilon-caprolactone), PCL polymer in vivo. Nu,
nuclei of FBGC. The PCL polymer was dissolved during sample preparation. Transmission electron microscopy (TEM),
bar = 2 μm. (B) In situ cross-section of the interface between a multinuclear giant cell (MnGC) and PLGA film. Note the
pseudopodia of the MnGC penetrated deep inside the surface of PLGA film and formed sealed compartments. PLGA
polymers are eroded within the compartments. Focused ion beam (FIB) microscopy, bar = 5 μm. (C) In situ cross-sec‐
tion of the interface between an osteoclasts-like cell (OC) and calcium phosphate cement. Note the typical ruffled
board of OC and vesicles (V) secreting from OC to the sealed extracellular space. FIB microscopy, bar = 2 μm [162].
12. Polyurethane (PU)
PU is a series of biomaterials that contains urethane radical and offers the greatest versatility
in compositions and properties of any family of polymers. Especially, a few specific elasto‐
meric PU compositions have demonstrated a combination of toughness, durability, biocom‐
patibility and biostability for being used as implantable medical devices, which is not
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achieved by any other available materials [181]. Because urethane is available in a very
broad hardness range (e.g. eraser-soft to bowling-ball-hard), it allows the engineer to replace
rubber, plastic and metal with the ultimate goals in abrasion resistance and physical proper‐
ties. During the last half century, PUs have become and remained the most valuable im‐
plantable elastomers for uses requiring toughness, durability, biocompatibility and
biostability [182]. With their inherently stable in the body environment, some of the PUs
have been widely used in medical applications such as synthetic heart valves, vascular
grafts, and pacemaker electrodes. However, these usages of PUs have been limited by three
major complications: calcification, thrombosis, and chemical degradation [183].
In the 1970s and 1980s as the PUs became recognized as the blood contacting material and
were used in a wide range of cardiovascular devices in long-term implants, they fell under
scrutiny with the failure of pacemaker leads and breast implant coatings in the late 1980s.
According to the manufacturer's report, high voltage coil fracture and PU defects were the
predominant causes of lead failure [184,185]. During the next decade PUs had been exten‐
sively researched for their relative sensitivity to biodegradation and the desire to further un‐
derstand the biological mechanisms for in vivo implantation [186,187]. Some investors have
seeded autologous sheep blood outgrowth endothelial cells (BOECs) on a cholesterol (Chol)-
modified PU (PU-Chol) heart valve leaflet to result in an intact, shear-resistant endothelium
that would promote resistance to thrombosis [188]. Because of the complex behavior of im‐
plantable PUs in the body environment, special attention to the choice of the constituted
components must be paid for designing and manufacturing the PU-containing devices. Sub‐
sequent treatment during sterilization, storage, implantation, in vivo operation and explanta‐
tion also determine the performance and provide the means for assessing the efficacy of the
PUs implants [189].
The most prominent disadvantages of PUs being used as artificial heart valves include min‐
eralization, environmental stress-cracking and oxidation. While the mechanisms of these
forms of degradation are not fully understood, an awareness of their causes and effects that
leads to all of the long-term functionality is required for the sophisticated PU-based devices
of today and tomorrow [190-191]. Over the last half century, extremely efforts have been
paid in the biomedical research field to improve the biocompatibilities and biodurability of
the PU implants, but only resulted in very little clinical effects [192-194].
In the later l990s a number of new bioresorbable materials with all the versatility of PUs in
terms of physical properties and biocompatibility have been yielded. AorTech Biomaterials
was set up in 1997 to commercialise a range of medical grade PUs developed by the Austral‐
ian research group (Commonwealth Scientific and Industrial Research Organization,
CSIRO). The company estimates that the worldwide market for surgical heart valve prod‐
ucts is worth more than $1bn (€705 m) and to be growing at a rate of 8% a year. Meanwhile,
the market for catheter-delivered heart valves is worth around $200 m (€141 mm) [195]. In
the authors’ own group in Tsinghua University, China, a novel PU made of PCL, PEG, and
1,6-hexmethyldiisocyanate has been synthesized. The hydrolytic degradation property of
the PU can be highly tuned by changing the composition and structure of copolymers, such
as PEG and PCL. When this kind of PU was used as a small-caliber (1.2 mm inner diameter)
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vein and nerve repair grafts it demonstrated excellent antithrombogenicity and superior bio‐
compatibility (Figure 9) [196,197].
Figure 9. An implantable small-diameter nerve and blood vessel repair PU conduit. (A) PU conduits with different in‐
ner diameters. (B) The PU conduit was connected to the vein of a rabbit. (C) The vein defect repair processes with a
very thin layer of fibrin-platelet deposition. (D) The nerve repair processes in rabbits with growing myelinated axons.
(E) The PU conduits degraded gradually in vivo in 12 weeks [196, 197].
13. Polytetrafluoroethylene (PTFE)
Polytetrafluoroethylene (PTFE), Discovered in 1938 by Roy J. Plunkett, is a synthetic high-
molecular-weight compound consisting wholly of carbon and fluorine with numerous ap‐
plications [198]. The best known brand name of PTFE is Teflon made by DuPont Co. It is
insoluble in all normally used organic solvents, not biodegradable in vivo and can suffer
high temperatures as 260 ℃ permanently. Clinically, PTFE has been widely used as a large
blood vessels repair materials.
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A 5 year research using PTFE-Gore-Tex grafts mainly for superficial femoral occlusion has
been conducted. The majority of the grafts were inserted in an elderly poor risk group of
patients with critical ischaemia of the lower limb. The overall cumulative patency at 2 years
was 29% falling to 18% at 5 years. Perioperative angiographic indicated that inflammatory
reaction is the only risk factor significantly affecting the cumulative graft patency. The pres‐
ence of diabetes was found to have a significant detrimental effect on limb salvage [199]. A
permanently implantable left ventricular assist device, made of Dacron velour, Teflon felt,
and Teflon-coated polyester fiber sutures, has been tested in chronic animal experiments. In
vivo experiments demonstrated that all components elicited mild to moderate inflammatory
reactions. Tissue responses to PTFE are rather passivated. Hematocele occurred only when
the components were implanted in the aorta with direct blood contact and exposed to arteri‐
al blood pressures [200]. An 8 cm long PTFE prosthesis was implanted into defects of the
abdominal aorta of dogs, and the following changes were found: the blood flow through the
vascular prosthesis induced a shortening of the blood clotting time and a slight increase in
the prothrombin consumption. It has a favourable effect of the sealing of pores in the pros‐
thesis and covering its internal surface with a fibrin membrane [201].
14. Silicone
Silicon is a metal in the same column as carbon in the periodic table with the symbol Si
and atomic number 14 [30].  It  is  the most  abundant element on earth and does not oc‐
cur  naturally  in  its  pure  metallic  state.  Dimethylsiloxane is  the  building block for  most
medical-grade  silicone  products,  including  breast  implants.  This  FDA  Grade  Silicone
sheeting is  commonly used in applications where food or  consumables  are  present.  For
more than 20  years  silicone miami breast  implants  have gone through a  lot  of  changes
since their first  uses.  After the mid-1980s many reports concerns the rupture rate of the
thinner-shell  products,  the  risk  of  subsequent  breast  cancer,  and  the  connective-tissue
diseases or symptoms in women with silicone gel-filled breast implants appeared. In the
United States a moratorium (in place since 1992) on the use of these prostheses has been
maintained by the pressure of overwhelming litigation. At the same time, Australian au‐
thorities also restricted the availability of silicone breast implants. Huge damages award‐
ed by United States  courts  forced Dow Corning,  manufacturer  of  a  large  percentage of
breast prostheses, to file for Chapter 11 bankruptcy in May 1995 [202].
As with any implantable medical devices or drugs, the risk of possible adverse effects must
always be weighed against the ability to provide benefits. A great deal of safety research
combined with more than 40 years of clinical experience has proven the efficacy and relative
safety of the silicone gel breast implants. A rough estimate of implant shell rupture rate is
~10% at 10 years with both biocompatibility and biodurability problems [203]. A fibrocon‐
nective tissue capsule was found around all the samples [204]. The capsule formed around
implanted mammary prosthesis is highly differentiated and organized, consisting of three
layers: interface layer in three variations, intermediate fibrous layer of dense rough collagen
fibers and light elongated cells with oval nucleus between them and adventitious layer. Be‐
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tween the fibers of the interface and the middle strata intra- and extracellular silicone drop‐
lets and bulks were observed, representing the location where further pathological
processes can take place [205]. It is said by Dr. Sidney Wolfe, director of Public Citizen's
Health Research Group, in a statement that: "Public Citizen continues to oppose the FDA's
2006 decision to return silicone breast implants to the market for cosmetic use in women for
augmentation. The agency's newer information about the risk of implant-associated lym‐
phoma and the previously known risks are serious enough to warrant advising women
against having these implanted.”
On March 9, 2012 a new silicone breast implant, which joins the two other silicone breast
implants on the market - one made by Allergan and the other by Mentor, was approved by
the FDA of the United States of America. Recommended monitoring after initially silicone
breast implantation is 3 years and then every two years thereafter. In a review Roach and
coworkers concern the importance of length and time on physicochemical interactions be‐
tween living tissue and biomaterials that occur on implantation. The review provides de‐
tailed information on material host interactions, dynamic material/cell surface states, surface
chemistry and topological roles during the first stage of implant integration, namely protein
adsorption. Generally, after the first contact of material with host tissue a state of flux due to
protein adsorption, cell adhesion and physical and chemical alteration of the implanted ma‐
terial is followed (Figure 10) [206]. This model can answer many questions concerning the
conformational form and bound proteins and therefore has instruction meanings in new im‐
plantable biomaterial design field.
Figure 10. Schematic of protein–surface interactions: Chemistry—adsorption onto biotinylated stripes which appear
white, whilst adsorption is hindered on square oligoethylene-glycol regions, the white box shows an intentionally
bleached area Topography—albumin adsorption onto hydrophilic silica spheres of varying dimensions as a model of
surface curvature [206].
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Beside the breast implants a silicon-silk transistor about one millimeter long and 250 nano‐
meters was created. So far the technique has been tested on mice with no adverse effects.
Electrical, bending, water dissolution, and animal toxicity studies suggest that this approach
might provide many opportunities for future biomedical devices and clinical applications
[207]. A silicone catheter attached to a 2-5 x 1-3 cm stainless steel chamber with a self sealing
injection port had been intravenously for antimicrobial chemotherapy. Peripheral venous ac‐
cess had become unsatisfactory in all of patients, and six had required central venous cathe‐
terisation [208]. More recently, a silicon-based neural probe with microfluidic channels was
developed [209].
Origins of controlled release of implantable drug delivery dates back to 1964 when silicone
implants were used to prolong a drug effect. Over 40 years, the progress to a safe, effective
and acceptable implant system has been slow. The critical factors in implant research which
need to be addressed include: erodibility, reproducibility, lack of irritation and carcinogenic‐
ity, lack of dose dumping, duration and pulses. While it is possible to surgically implant and
remove drug-containing devices or polymeric matrices, the requirement for such interven‐
tion could have a significant negative impact on the acceptability of a product candidate. In
recent years, two implant systems have been approved for human use; (a) a silicone-based
device (NorplantR), and (b) a system based on lactide/glycolide copolymers to release a lutei‐
nizing hormone - releasing hormone (LHRH) agonist for treatment of male reproductive
tract tumours. This drug delivery approach is very appealing for a number of classes of
drugs, particularly those that cannot be given via the oral route, and drug candidates whose
therapeutic index is relatively large [210].
15. Aluminium (or aluminum) and ceramics
Aluminium (or aluminum) is the third most abundant chemical element (after oxygen and
silicon in the boron group) with symbol Al and atomic number 13. It is one of the typical
metals which has been widely used as hard tissue repair materials with unique properties,
such as strong mechanical strength, not soluble and degradable in body fluid under normal
circumstances, combined in over 270 different minerals, low density (weight) and corrosion
resistances [211]. It is generally accepted that metallic implant materials with higher
strength/modulus ratios are more favorable for hard tissue repair due to a combined effect
of high strength and reduced stress-shielding risk [212].
Al alloys, such as Al-silicon (Si), Al-platinum, and Al-titanium (Ti) are widely used in im‐
plantable engineering structures and components where light weight or corrosion resistance
is required except for blood-contacting surfaces [213,214]. For example, an implantable dou‐
ble-sided electrode microdevices, called flexible nerve plates, with a prototype of Al layer
could reduce the number of insertion sites and thereby the insertion trauma during implan‐
tation of neural prostheses [215]. A Ti-6Al-4vanadium (V) alloy was selected as the ceramic-
to-metal seal because its excellent mechanical properties and favorable biocompatibility
[216]. The first-generation of implantable left ventricular assist devices (LVADs) were Ti-Al-
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vanadium alloy pulsatile, volume-displacement pumps. The modern LVAD era began with
the introduction of the HeartMate X (vented electric) VE in 1998 [217]. These devices can
provide excellent circulatory support and improve survival until heart transplantation.
However, they have many application limitations, such as a large volume, an excessive sur‐
gical dissection, a large diameter driveline, a noisy pump operation, and particularly a limit‐
ed mechanical durability. Other complications include bleeding, infections and
thromboembolic events. During the succeeding decade, vast improvements in pump design
resulted in a new crop of LVADs, whose attributes are transforming LVAD therapy into a
kind of standard of care for end-stage heart failure [218]. LVAD therapy has now evolved
into a solution which is strikingly superior to optimal medical therapy [219, 220].
It was reported that changes in the porous hydroxyapatite and Al oxide orbital implant den‐
sities may correspond to healing and maturation of soft tissues surrounding and penetrating
the implants [221]. The thermal oxidation behavior of Al ion implanted Ti nitride films has
been studied in dry oxygen atmosphere and found that Al implantation caused the oxida‐
tion rate of TiN films to slow down at the initial stage of oxidation [222]. Until recently,
there is limited evidence regarding comparative effectiveness of various hip implant bear‐
ings, especially metal on metal or ceramic on ceramic implants compared with traditional
metal on polyethylene or ceramic on polyethylene bearings [223].
For clinical applications, it is an important character that the metal devices do not cause
mental or body uncomfortable reactions, such as delaminate or infiltrate ions to the sur‐
round tissues. For example, a defibrillator is a medical device that generates and delivers a
shock to the heart of someone in cardiac arrest. Although this device can save lives, there are
risks involved, for both the patient and the first responders. One risk associated with defib‐
rillator use is that of burns. Certain transdermal medication patches contain aluminum back‐
ings, and when they come in contact with the defibrillator paddle, can cause minor burns to
the patient. Accidental shocks to others can occur when first responders accidentally contact
with the patient who is being defibrillated. The only objects that should touch the patient
during treatment are the defibrillator paddles held by the administrator of the procedure.
Sometimes internally implanted defibrillators discharge shocks when they are unnecessary.
When this occurs, it can cause pain and promote a dangerous heart rhythm. In addition, the
event can be emotionally disturbing and frightening. Doctor can recalibrate the device to
minimize the risk of additional unnecessary shocks, and offer suggestions on how to man‐
age these rare events [224].
A ceramic is an inorganic, nonmetallic solid material possessing strong mechanical proper‐
ties prepared by the action of heat and subsequent cooling [30]. The uses of ceramics have
been revolutionizing the biomedical field in deployment as implants for humans during the
past three decades. In the search to improve the biocompatibility and mechanical strength of
skeletal implant materials, attention has been directed towards the potential use of ceramic
composites [225]. Since 1975 alumina ceramic has proven its bioinertness and have been ac‐
cepted in biomedical applications, some alumina ceramic, such as Al2O3 has been character‐
ized with high hardness and high abrasion resistance. Noiri and coworkers evaluated the
biocompatibility of alumina-ceramic material histopathalogically for eight weeks by im‐
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planting in the eye sockets of albino rabbits with no signs of implant rejection or prolapse of
the implanted pieces. After a period of four weeks of implantation, fibroblast proliferation
and vascular invasion were noted. By the eighth week, tissue growth was observed in the
pores of the implants [226].
Figure 11. Scanning electron microscopy (SEM) images of SaOS-2 cells cultured for 48 h on micropatterned Ti (A-D)
and diamond-like carbon (DLC) (E, F) surfaces. Large-sized (125 µm) squared (A) and circular (B) features facilitated the
adhesion of several cells on one Ti island with the cells aligning themselves along the edges of the cell-friendly materi‐
al. The cells adhering to mediumsized Ti islands no longer conformed strictly to the geometrical shape of the patterns
(C) but particularly on circularly patterned surfaces, star-like cellular morphologies appeared (D). On small-sized in‐
verse DLC samples, the cell bodies non-selectively covered large micro-patterned areas (E), but their filopodia clearly
showed a preference for DLC trying to avoid bare Si circles (F) [222].




Biocompatible is a vital important aspect for an implantable biomaterial. Among the numer‐
ous types of host responses to a broad spectrum of biomaterials, those with no adverse or
negative effects, such as, fibrous encapsulation, osteolysis, hyperplasia, and inflammation
are among the most expectant ones. As advances are made in biomaterial science and tech‐
nology, new implants/medical devices will be continually explored, alternatives to conven‐
tional implants will become more and more effective, and hence more and more attractive.
In an effort to provide the best clinical outcomes for the patients, we need to develop the
best candidates with minimum invasive surgery times and unnecessary health risks. In the
future, design and manufacture immuno or low-immuno implantable biomaterials accord‐
ing to or mimicking the patients’ own ingredients, such as blood components, ECMs, tissues
and organs, will be possible. For an implantable biomaterial biocompatibility should be al‐
ways put into the primary importance position no matter it is used as a temporary scaffold,
a permanent template, or a drug delivery vihicle.
Acknowledgment
Work in the authors’ laboratory is supported by the State Key Laboratory of Materials Proc‐
essing and Die & Mould Technology, Huazhong University of Science and Technology (No.
2012 - P03), the National Natural Science Foundation of China / the Research Grants Council
of Hong Kong (NSFC/RGC, No. 50731160625), the National Natural Science Foundation of
China (No. 81271665 & 30970748), the National High Tech 863 Grant (No. 2009AA043801),
the Finland Distinguished Professor program (FiDiPro) of Tekes (No. 40041/10), and the
Cross-Strait Tsinghua Cooperation Basic Research (No.2012THZ02-3).
Author details
Xiaohong Wang1,2,3
Address all correspondence to: wangxiaohong@tsinghua.edu.cn
1 Key Laboratory for Advanced Materials Processing Technology, Ministry of Education &
Center of Organ Manufacturing, Department of Mechanical Engineering, Tsinghua Univer‐
sity, Beijing, P.R. China
2 Business Innovation Technology (BIT) Research Centre, School of Science and Technology,
Aalto University, Aalto, Finland
3 State Key Laboratory of Materials Processing and Die & Mould Technology, Huazhong
University of Science and Technology, Wuhan, P.R. China
Advances in Biomaterials Science and Biomedical Applications138
References
[1] Tathe A, Ghodke M, Nikalje AP. International Journal of Pharmacy and Pharmaceut‐
ical Sciences ( Int J Pharm Pharm Sci) 2010;2(4):19-23.
[2] Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semi‐
nars in Immunology 2008;20 (2): 86–100.
[3] Patel NR, Gohil PP. A review on biomaterials: scope, applications & human anatomy
significance. International Journal of Emerging Technology and Advanced Engineer‐
ing 2012; 2(4): 91-101.
[4] Seal BL, Otero TC, Panitch A. Polymeric biomaterials for tissue and organ regenera‐
tion. Materials Science and Engineering R 2001;34:147-230.
[5] Franz S, Rammelt S, Scharnweber D, Simon JC. Immune responses to implants - A
review of the implications for the design of immunomodulatory biomaterials. Bioma‐
terials 2011;32(28): 6692-6709
[6] Medical-dictionary.thefreedictionary.com.




[10] Hodde J. Naturally occurring scaffolds for soft tissue repair and regeneration. Tissue
Eng 2002;8:295-308.
[11] Thomas W. Gilbert, Tiffany L. Sellaro, Stephen F. Badylak. Decellularization of tis‐
sues and organs. Biomaterials 2006;27(19): 3675–3683.
[12] Patino MG, Neiders ME, Andreana S, Noble B, Cohen RE. Collagen as an implanta‐
ble material in medicine and dentistry. J Oral Implantol. 2002;28(5):220-225.
[13] Wang XH, Yan YN, Zhang RJ. A comparison of chitosan and collagen sponges as
heostatic sressings. J Bioact Compat Polym 2006;21(1)::39-54.
[14] George D. Kymionis, Michael A. Grentzelos, Alexandra E. Karavitaki, Zotta Paraske‐
vi, Sonia H. Yoo, Ioannis G. Pallikaris. Combined corneal collagen cross-linking and
posterior chamber toric implantable collamer lens implantation for keratoconus.
Ophthalmic Surgery, Lasers and Imaging. DOI: 10.3928/15428877-20110210-0.
[15] Ju YM, Yu B, West L, Moussy Y, Moussy F. A dexamethasone-loaded PLGA micro‐
spheres/collagen scaffold composite for implantable glucose sensors. J Biomed Mater
Res A. 2010;93(1):200-210.
Overview on Biocompatibilities of Implantable Biomaterials
http://dx.doi.org/10.5772/53461
139
[16] Hou ZQ, Sun Q, Wang Q, Han J, Wang Y, Zhang QQ. In vitro and in vivo evaluation
of novel implantable collagen–chitosan–soybean phosphatidylcholine composite film
for the sustained delivery of mitomycin C. Drug Dev Res 2009;70(3):169-219.
[17] Ward, A.G.; Courts, A. The Science and Technology of Gelatin. New York: Academic
Press. 1977;ISBN0-12-735050-0.
[18] Kakiuchi M, Hosoya T, Takaoka K, Amitani K, Ono K. Human bone matrix gelatin as
a clinical alloimplant. A retrospective review of 160 cases. Int Orthop 1985;9(3):
181-188.
[19] Wang XH, Yan YN, Zhang RJ. Gelatin-based hydrogels for controlled cell assembly.
In: Ottenbrite RM, ed. Biomedical Applications of Hydrogels Handbook. New York:
Springer, 2010;269-284.
[20] Wang XH, Yan YN, Zhang RJ Rapid prototyping as a tool for manufacturing bioarti‐
ficial livers. Trends Biotechnol 2007;25:505-513.
[21] Wang XH, Yan YN, Zhang RJ. Recent trends and challenges in complex organ manu‐
facturing. Tissue Eng Part B 2010;16:189-197.
[22] Wang XH, Zhang QQ. Overview on “Chinese–Finnish workshop on biomanufactur‐
ing and evaluation techniques. Artificial Organs 2011;35(10):E191- E193.
[23] Wang XH. Intelligent freeform manufacturing of complex organs. Artificial Organs.
2012; doi:10.1111/j.1525-1594.2012.01499.x.
[24] Xu W, Wang XH, Yan YN, Zhang RJ. A polyurethane-gelatin hybrid construct for
manufacturing implantable bioartificial livers. J Bioact Compat Polym 2008;23(5):
409-422.
[25] He K, Wang XH. Rapid prototyping of tubular polyurethane and cell/hydrogel con‐
struct. J Bioact Compat Polym 2011;26(4):363-374.
[26] Kimura Y, Ozeki M, Inamoto T, Tabata Y. Adipose tissue engineering based on hu‐
man preadipocytes combined with gelatin microspheres containing basic fibroblast
growth factor. Biomaterials 24 (2003) 2513–2521.
[27] Liu J. Controlled trans-lymphatic delivery of chemotherapy for the treatment of lym‐
phatic metastasis in lung cancer. A thesis submitted in conformity with the require‐
ments for the degree of Doctor of Philosophy Institute of Medical Science, University
of Toronto, 2008.
[28] Ozeki M, Ishii T, Hirano Y, Tabata Y. Controlled release of hepatocyte growth factor
from gelatin hydrogels based on hydrogel degradation. J Drug Target. 2001;9(6):
461-471.
[29] Yang Z, Xu LS, Yin F, Shi YQ, Han Y, Zhang L, Jin HF, Nie YZ, Wang JB, Hao X, Fan
DM, Zhou XM. In vitro and in vivo characterization of silk fibroin/gelatin composite
scaffolds for liver tissue engineering. J Dig Dis. 2012 Mar;13(3):168-178.
Advances in Biomaterials Science and Biomedical Applications140
[30] en.wikipedia.org/wiki, the free encyclopedia.
[31] Radosevich M, Goubran H, Burnouf T. Fibrin sealant: scientific rationale, production
methods, properties and current clinical use. Vox Sang 1997;72:133-143.
[32] Dunn C, Goa K. Fibrin sealant: a review of its use in surgery and endoscopy. Drugs
1999;58:863-886.
[33] Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005;70:247-299.
[34] Clark RA. Fibrin is a many splendored thing. J Invest Dermatol 2003;121(5):xxi-xxii.
[35] Herrick S, Blanc-Brude O, Gray A, Laurent G. Fibrinogen. Int J Biochem Cell Biol
1999;31(7):741-746.
[36] Abiraman S, Varma HK, Umashankar PR, John A. Fibrin glue as an osteoinductive
protein in a mouse model. Biomaterials 23 (2002) 3023–3031.
[37] Hwang TL, Chen MF. Randomized trial of fibrin tissue glue for low output enterocu‐
taneous fistula. Br J Surg 1996;83:112.
[38] Flanagan TC, Sachweh JS, Frese J, Schnöring H, Gronloh N, Koch S, Tolba RH,
Schmitz-Rode T, Jockenhoevel S. In vivo Remodeling and Structural Characterization
of Fibrin-Based Tissue-Engineered Heart Valves in the Adult Sheep Model. Tissue
Engineering Part A. 2009;15(10):2965-2976.
[39] Mol A, Driessen NJ, Rutten MC, Hoerstrup SP, Bouten CV, and Baaijens FP. Tissue
engineering of human heart valve leaflets: a novel bioreactor for a strain-based con‐
ditioning approach. Ann Biomed Eng 2005;33(12):1778-1788
[40] Barsotti MC, Felice F, Balbarini A, Di Stefano R. Fibrin as a scaffold for cardiac tissue
engineering. Biotechnol Appl Biochem 2011;58(5):301-310.
[41] Peretti GM, Xu JW, Bonassar LJ, Kirchhoff CH, Yaremchuk MJ, Randolph MA. Re‐
view of injectable cartilage engineering using fibrin gel in mice and swine models.
Tissue Eng. 2006;12(5):1151-1168.
[42] Daniel D. Swartz, James A. Russell, Stelios T. Andreadis. Engineering of fibrin-based
functional and implantable small-diameter blood vessels. Am J Physiol Heart Circ
Physiol 2005;288: H1451–H1460.
[43] Sameem M, Wood TJ, Bain JR. A systematic review on the use of fibrin glue for pe‐
ripheral nerve repair. Plast Reconstr Surg. 2011;127(6):2381-2390.
[44] Koch S, Flanagan TC, Sachweh JS, Tanios F, Schnoering H, Deichmann T, Ellä V, Kel‐
lomäki M, Gronloh N, Gries T, Tolba R, Schmitz-Rode T, Jockenhoevel S. Fibrin-poly‐
lactide-based tissue-engineered vascular graft in the arterial circulation. Biomaterials
2010;31(17):4731-4739
[45] Guéhennec LL, Daculsi G. A review of bioceramics and fibrin sealant. LE.u Lroe
pGeuanéh Ceenlnles ca netd aMl.aterials 2004;8: 1-11.
Overview on Biocompatibilities of Implantable Biomaterials
http://dx.doi.org/10.5772/53461
141
[46] Jeffrey M. Karp JM, Sarraf F, Shoichet MS, Davies JE. Fibrin-filled scaffolds for bone-
tissue engineering: An in vivo study. J Biomed Mater Res 2004;71A:162–171.
[47] Farhat WA, Chen J, Sherman C, Cartwright L, Bahoric A, Yeger H. Impact of fibrin
glue and urinary bladder cell spraying on the in-vivo acellular matrix cellularization:
a porcine pilot study. Can J Urol 2006;13(2):3000-3008.
[48] Breen A, O'Brien T, and Pandit A. Fibrin as a Delivery System for Therapeutic Drugs
and Biomolecules. Tissue Eng Part B Rev. 2009;15(2):201-214.
[49] Briganti E, Spiller D, Mirtelli C, Kull S, Counoupas C, Losi P, Senesi S, Di Stefano R,
and Soldani G. A. Composite fibrin-based scaffold for controlled delivery of bioac‐
tive pro-angiogenetic growth factors. J Control Release 2010;142(1):14-21.
[50] Jockenhoevel S, Zund G, Hoerstrup SP, Chalabi K, Sachweh JS, Demircan L, Messm‐
er BJ, Turina M. Fibrin gel -- advantages of a new scaffold in cardiovascular tissue
engineering. Eur J Cardiothorac Surg 2001;19(4):424-430.
[51] Catelas I, Dwyer JF, and Helgerson S. Controlled release of bioactive transforming
growth factor Beta-1 from fibrin gels in vitro. Tissue Eng Part C Methods 2008;14(2):
119-128.
[52] Arkudas A, Pryymachuk G, Hoereth T, Beier JP, olykandriotis E, Bleiziffer O, Horch
RE, and Kneser U. Dose- Finding Study of Fibrin Gel-Immobilized Vascular Endo‐
thelial Growth Factor 165 and Basic Fibroblast Growth Factor in the Arteriovenous
Loop Rat Model. Tissue Eng Part A. 2009;15(9):2501-2511.
[53] Breen A, O'Brien T, and Pandit A. Fibrin as a Delivery System for Therapeutic Drugs
and Biomolecules. Tissue Eng Part B Rev 2009;15(2):201-214.
[54] Sakiyama SE, Schense JC, and Hubbell JA. Incorporation of heparin-binding peptides
into fibrin gels enhances neurite extension: an example of designer matrices in tissue
engineering. FASEB J. 1999;13(15):2214-2224.
[55] Zisch AH, Schenk U, Schense JC, Sakiyama-Elbert SE, and Hubbell JA. Covalently
conjugated VEGF—fibrin matrices for endothelialization. J Control Release
2001;72(1-3):101-113.
[56] Hara T. Bhayana B, Thompson B, Kessinger CW, McCarthy AKR, Weissleder R, Lin
CP, Tearney GJ, Jaffer FA. Molecular Imaging of Fibrin Deposition in Deep Vein
Thrombosis Using Fibrin-Targeted Near-Infrared Fluorescence. J Am Coll Cardiol
Img 2012;5:607–1551.
[57] Ruszymah BH. Autologous human fibrin as the biomaterial for tissue engineering.
Med J Malaysia 2004;59(Suppl B):30-31.
[58] Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R, Baigent C. Towards
evidence-based guidelines for the prevention of venous thromboembolism: systemat‐
ic reviews of mechanical methods, oral anticoagulation, dextran and regional anaes‐
thesia as thromboprophylaxis. Health Technol Assess 2005;9(49):iii-iv, ix-x, 1-78.
Advances in Biomaterials Science and Biomedical Applications142
[59] Sophie R. Tomme V, Hennink WE. Biodegradable dextran hydrogels for protein de‐
livery applications. Expert Review of Medical Devices 2007;4:147-164.
[60] Atik M. Dextran 40 and Dextran 70. A Review. Arch Surg 1967;94(5):664-672.
[61] Dubick MA, Wade CE. A review of the efficacy and safety of 7.5% NaCl/6% dextran
70 in experimental animals and in humans. J Trauma 1994;36(3):323-330.
[62] Richardson D, Deakin CD. Hypertonic saline dextran. A review of current literature.
Scand J Trauma Resusc Emerg Med. 2004;12:142-146.
[63] Sun GM, Zhang XJ, She Y-I, Sebastian R, Dickinson LE, Fox-Talbot K, Reinblatt M,
Steenbergen C, Harmon JW, Gerecht S. Dextran hydrogel scaffolds enhance angio‐
genic responses and promote complete skin regeneration during burn wound heal‐
ing. PNAS 14, 2011;108:20975-20980.
[64] Draye J-P, Delaey B, Van de Voorde A. Van Den Bulcke A, Reu BD, Schacht E. In vi‐
tro and in vivo biocompatibility of dextran dialdehyde cross-linked gelatin hydrogel
films. Biomaterials 1998;19(18):1677-1687.
[65] Groot CJD, Van Luyn MJA, Van Dijk-Wolthuis WND, Cadée JA, Plantinga JA, Otter
WD, Hennink WE. In vitro biocompatibility of biodegradable dextran-based hydro‐
gels tested with human fibroblasts. Biomaterials 2001;22(11):1197-1203.
[66] Dhaneshwar SS, Kandpal M, Gairola N, Kadam SS. Dextran: a promising macromo‐
lecular drug carrier. Indian Journal of Pharmaceutical Sciences 2006;68(6):705-714.
[67] de Belder AN. Dextran. Hndbooks from Amersham bosciences. 18-1166-12, Edition
Amersham AA. Biosciences AB 2003. (ww.amershambiosciences.com.)
[68] Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R, Baigent C. Towards
evidence-based guidelines for the prevention of venous thromboembolism: systemat‐
ic reviews of mechanical methods, oral anticoagulation, dextran and regional anaes‐
thesia as thromboprophylaxis. Health Technology Assessment 2005;9:(49): Editor-in-
Chief: Professor Tom Walley. 2005 Crown Copyright.
[69] Solomon L, Mansor S, Mallon P, Donnelly E, Hoper M, Loughrey M, Kirk S, Gardin‐
er K. The dextran sulphate sodium (DSS) model of colitis: an overview. Comp Clin
Pathol 2010;19:235–239.
[70] Yang J, Liu Y, Wang H, Liu L, Wang W, Wang C, Wang Q, Liu W. The biocompatibil‐
ity of fatty acid modified dextran-agmatine bioconjugate gene delivery vector. Bio‐
materials 2012;33(2):604-613.
[71] Necas J, Bartosikova L, Brauner P, Kolar J. Hyaluronic acid (hyaluronan): a review.
Veterinarni Medicina, 2008;53(8):397–411.
[72] Frasher JRE; Laurent TC; Laurent UBG. Hyaluronan: its nature, distribution, func‐
tions and turnover. Journal of Internal Medicine 1997;242(1):27–33.
Overview on Biocompatibilities of Implantable Biomaterials
http://dx.doi.org/10.5772/53461
143
[73] Kahmann JD, O’Brien R, Werner JM, Heinegard D, Ladbury JE, Campbell ID, Day
AJ. Localization and characterization of the hyaluronan-binding site on the Link
module from human TSG-6. Structure 2000;8:763–774.
[74] Jaracz S, Chen J, Kuznetsova LV, Ojima I. Recent advances in tumor-targeting anti‐
cancer drug conjugates. Bioorganic and Medicinal Chemistry 2005;13:5043–5054.
[75] Paiva P, Van Damme MP, Tellbach M, Jones RL, Jobling T, Salamonsen LA. Expres‐
sion patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a
role for hyaluronan in the progression of endometrial cancer. Gynecologic Oncology
2005;3:202.
[76] Lokeshwar, VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, Escudero
DO, Dhir N, Altman N. Antitumor activity of hyaluronic acid synthesis inhibitor 4-
methylumbelliferone in prostate cancer cells. Cancer Res 2010;70(7):2613–2623.
[77] Amarnath LP, Srinivas A, Ramamurthi A. In vitro hemocompatibility testing of UV-
modified hyaluronan hydrogels. Biomaterials 2006; 27(8):1416–1424.
[78] Jansen K., van der Werff JFA, van Wachem PB, Nicolai JPA, de Leij L.F.M.H, van
Luyn MJA. A hyaluronan-based nerve guide: in vitro cytotoxicity, subcutaneous tis‐
sue reactions, and degradation in the rat. Biomaterials 2004;25(1):483–489.
[79] Rah MJ. A review of hyaluronan and its ophthalmic applications. Optometry
2011;82(1):38-43.
[80] De Andrés Santos MI, Velasco-Martín A, Hernández-Velasco E, Martín-Gil J, Martín-
Gil FJ. Thermal behaviour of aqueous solutions of sodium hyaluronate from different
commercial sources". Thermochim Acta 1994;42:153-160.
[81] Peattie RA, Rieke E, Hewett E, Fisher RJ, Shu XZ, Prestwich GD. Dual growth factor-
induced angiogenesis in vivo using hyaluronan hydrogel implants.Biomaterials 2006;
27 (9):1868-1875,
[82] Pike DB, Cai S, Pomraning KR, Firpo MA, Fisher RJ, Shu XZ, Prestwich GD, Peattie
RA. Heparin-regulated release of growth factors in vitro and angiogenic response in
vivo to implanted hyaluronan hydrogels containing VEGF and Bfgf. Biomaterials
2006;27(30):5242–5251.
[83] Dianhua Jiang, Jiurong Liang, Paul W. Noble. Hyaluronan as an Immune Regulator
in Human Diseases. Physiol Rev January 1, 2011 vol. 91 no. 1 221-264.
[84] Jiang DH, Liang JR, Noble PW. Hyaluronan in Tissue Injury and Repair. Annual Re‐
view of Cell and Developmental Biology 2007;23:435-461.
[85] Luke R. Bucci, Amy A. Turpin. Will the real hyaluronan please stand up? Journal of
applied nutrition 2004;54(1):10-33.
[86] Longaker MT, Chiu ES, Adzick NS, Stem M, Harrison MR, Stem R. Studies in fetal
wound healing: V. A prolonged presence of hyaluronic acid characterizes fetal
wound fluid. Annals of Surgery. Annals of Surgery 1991;213(4):292-296.
Advances in Biomaterials Science and Biomedical Applications144
[87] Chen WYJ, Giovanni Abatangelo G. Functions of hyaluronan in wound repair.
Wound Repair and Regeneration 1999;7(2):79-89.
[88] Benedetti L, Cortivo R, Berti T, Berti A, Pea F, Mazzo M, Moras M, Abatangelo G.
Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) im‐
planted in rats. Biomaterials 1993;14(15):1154-1160.
[89] Shen X, Tanaka K, Takamori A. Coronary arteries angiogenesis in ischemic myocar‐
dium: biocompatibility and biodegradability of various hydrogels. Artificial Organs
2009;33(10):781-787.
[90] Praveen SS, Hanumantha R, Belovich JM, Davis BL. Novel hyaluronic acid coating
for potential use in glucose sensor design. Diabetes Technol Ther. 2003;5(3):393-399.
[91] Hou SP, Xu QY, Tian WM, Cui FZ, Cai Q, Ma J, Lee I-S. The repair of brain lesion by
implantation of hyaluronic acid hydrogels modified with laminin. Journal of Neuro‐
science Methods 2005;148:60–70.
[92] Zhang T, Yan YN, Wang XH, Xiong Z, Lin F, Wu RD, Zhang RJ. Three-dimensional
gelatin and gelatin/hyaluronan hydrogel structures for traumatic brain injury. J Bio‐
act Compat Polym 2007;22(1):19-29.
[93] Avitabile T, Marano F, Castiglione F, Bucolo C, Cro M, Ambrosio L, Ferrauto C, Rei‐
baldi A. Biocompatibility and biodegradation of intravitreal hyaluronan implants in
rabbits. Biomaterials 2001;22(3):195-200.
[94] Li H, Liu Y, Shu XZ, Gray SD, Prestwich GD. Synthesis and biological evaluation of a
cross-linked hyaluronan-mitomycin C hydrogel. Biomacromolecules 2004;5(3):
895-902.
[95] Zheng SX, Liu Y, Palumbo FS, Luo Y, Prestwich GD. In situ crosslinkable hyaluronan
hydrogels for tissue engineering. Biomaterials 2004;25(7-8):1339-1348.
[96] Hong HJ, Lee JS, Choi JW, Min BH, Lee HB, Kim CH. Transplantation of Autologous
Chondrocytes Seeded on a Fibrin/Hyaluronan Composite Gel Into Tracheal Cartilage
Defects in Rabbits: Preliminary Results. Artif Organs 2012;30:1525-1594.
[97] Cox M; Nelson D. Lehninger, Principles of Biochemistry. Freeman 2004:1100.
[98] Jang I-K, Hursting MJ. When Heparins Promote Thrombosis : Review of Heparin-In‐
duced Thrombocytopenia. Circulation 2005;111:2671-2683.
[99] Moore BR, Hinchcliff KW. Heparin: a review of its pharmacology and therapeutic
use in horses. J Vet Intern Med. 1994;8(1):26-35.
[100] Saliba Jr MJ . Heparin in the treatment of burns: a review. Burns 2001;27(4):349-358.
[101] Papa A, Danese S, Gasbarrini A, Gasbarrini G. Review article: potential therapeutic
applications and mechanisms of action of heparin in inflammatory bowel disease.
Aliment Pharmacol Ther. 2000 Nov;14(11):1403-1409.
Overview on Biocompatibilities of Implantable Biomaterials
http://dx.doi.org/10.5772/53461
145
[102] Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the
post-thrombotic syndrome: a systematic review. Am J Med. 2011;124(8):756-765.
[103] Wang XH, Yan YN, Lin F, Xiong Z, Wu RD, Zhang RJ, Lu QP. Preparation and char‐
acterization of a collagen/chitosan/heparin matrix for an implantable bioartificial liv‐
er. J Biomater Sci.Polym Ed 2005;16(9):1063-1080.
[104] Yu X, Bichtelen A, Wang XH, Yan YN, Lin F, Xiong Z, Wu RD, Zhang RJ, Lu QP. Col‐
lagen/chitosan/heparin complex with improved biocompatibility for hepatic tissue
engineering. J Bioact Compat Polym 2005;20(1):15-28.
[105] Matthew D. Mitchell, Barbara Jo Anderson, Kendal Williams & Craig A. Umscheid.
Heparin flushing and other interventions to maintain patency of central venous cath‐
eters: a systematic review. Journal of Advanced Nursing 2009;65(10), 2007–2021.
[106] Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syn‐
drome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet
Gynecol. 2010;115(6):1256-1262.
[107] Marcum JA, McKenney JB, Galli SJ, Jackman RW, Rosenberg RD. Anticoagulantly ac‐
tive heparin-like molecules from mast cell-deficient mice. Am J Physiol 1986;250 (5 Pt
2): H879–888.
[108] Nader HB, Chavante SF, dos-Santos EA, Oliveira FW, de-Paiva JF, Jerônimo SMB,
Medeiros GF, de-Abreu LRD, Leite EL, de-Sousa-Filho JF, Castro RAB, Toma L, Ter‐
sariol ILS, Porcionatto MA, Dietrich CP. Heparan sulfates and heparins: similar com‐
pounds performing the same functions in vertebrates and invertebrates? Braz J Med
Biol Res 1999;32(5):529–538.
[109] Peattie RA, Rieke E, Hewett E, Fisher RJ, Shu X Z, Prestwich G D. Dual growth fac‐
tor-induced angiogenesis in vivo using hyaluronan hydrogel implants. Biomaterials
2006;27(9):1868-1875.
[110] Swanson JM. Heparin-induced thrombocytopenia: a general review. J Infus Nurs.
2007;30(4):232-240.
[111] Hong MS, Amanullah AM. Heparin-induced thrombocytopenia: a practical review.
Rev Cardiovasc Med 2010;11(1):13-25.
[112] James L. Januzzi, Jr. and Ik-Kyung Jang. Heparin Induced Thrombocytopenia: Diag‐
nosis and Contemporary Antithrombin Management. J Thromb Thrombolysis
1999;7:259–264.
[113] Strand BL, Ryan L, Veld PI, Kulseng B, Rokstad AM, Skjåk-Bræk G., Especik T. Cell
Transplant. 2001;10:263-275.
[114] Yao R, Zhang RJ, Yan YN, Wang XH. In vitro angiogenesis of 3D tissue engineered
adipose tissue. J Bioact Compat Polym 2009;24(1):5-24.
[115] Yao R, Zhang RJ, Wang XH. Design and evaluation of a cell microencapsulating de‐
vice for cell assembly technoloty. J Bioact Compat Polym 2009;24(1):48-62.
Advances in Biomaterials Science and Biomedical Applications146
[116] Soon-Shiong P, Heintx RE, Merideth N, Yao QX, Yao Z, Zheng T, Murphy M, Molo‐
ney MK, Schmedhl M, Harris M, Mendez R, Mendez R, Sanford PA. The Lancet
1994;16:950-951.
[117] Li RH. Materials for Immunoisolated Cell Transplantation. Advanced Drug Delivery
Reviews 1998;33:87–109.
[118] Tam SK, de Haan BJ, Faas MM, Hallé JP, Yahia L, de Vos P. Adsorption of human
immunoglobulin to implantable alginate-poly-L-lysine microcapsules: effect of mi‐
crocapsule composition. J Biomed Mater Res A. 2009;89(3):609-615.
[119] Xie H-G, Li X-X, Lv G-J, Xie W-Y, Zhu J, Luxbacher T, Ma R, Ma X-J. Laboratory of
Biomedical MaterialDevelopment of an implantable alginate scaffold for the treat‐
ment of spinal cord trauma. J Biomed Mater Res 2010;92A:1357–1365.
[120] Shahidi F, Synowiecki J. Isolation and characterization of nutrients and value-added
products from snow crab (Chionoecetes opilio) and shrimp (Pandalus borealis) proc‐
essing discards. Journal of Agricultural and Food Chemistry (American Chemical So‐
ciety) 1991;39 (8): 1527–1532.
[121] Khor E, Lim LY. Implantable applications of chitin and chitosan. Biomaterials. 2003;
24(13):2339-2349.
[122] Yang T-L. Chitin-based Materials in tissue engineering: applications in soft tissue
and epithelial organ. Int J Mol Sci 2011;12:1936-1963.
[123] Costa-Pinto AR, Reis RL, Neves NM. Scaffolds based bone tissue engineering: the
role of chitosan. Tissue Engineering Part B 2011;17(5):1-17.
[124] Wang XH, Yu X, Yan YN, Zhang RJ. Liver tissue responses to gelatin and gelatin/
chitosan gels. J Biomed Mater Res 2008;87A(1):62-68.
[125] Michael Dornish, VP research and development, and Dr Are Kristiansen, commercial
development manager, at FMC BioPolymer.
[126] Khor E, Lim LY. Implantable applications of chitin and chitosan. Biomaterials 2003;24
(13):2339–2349.
[127] Mi FL, Tan YC, Liang HC, Huang RN, Sung HW. In vitro evaluation of a chitosan
membrane cross-linked with genipin. J Biomater Sci Polym Ed 2001;12(8):835-850.
[128] Wang XH, Ma JB, Wang YN, He BL. Structural characterization of phosphorylated
chitosan and their applications as effective additives of calcium phosphate cements.
Biomaterials 2001;22(16):2247-2255.
[129] Wang XH, Ma JB, Wang YN, He BL. Skeletal repair in radii and tibias of rabbits with
phosphorylated chitosan reinforced calcium phosphate cements. Biomaterials.
2002;23(21):4167-4176.
[130] Wang XH, Ma JB, Wang YN, He BL. Reinforcement of calcium phosphate cements
with phosphorylated chitin. Chin J Polym Sci 2002;4:325-332.
Overview on Biocompatibilities of Implantable Biomaterials
http://dx.doi.org/10.5772/53461
147
[131] Wang XH, Ma JB, Feng QL, Cui FZ. Skeletal repair in rabbits with calcium phosphate
cements incorporated phosphorylated chitin. Biomaterials 2002;23(23):4591-4600.
[132] Wang XH, Ma JB, Feng QL, Cui FZ. in vivo evaluation of S-chitosan enhanced calci‐
um phosphate cements. J Bioact Compat Polym 2003;18(4):259-271.
[133] Wang XH, Feng QL, Cui FZ, Ma JB. The effects of S-chitosan on the physical proper‐
ties of calcium phosphate cements. J Bioact Compat Polym 2003;18(1):45-57.
[134] Liu H, Mao J, Yao K, Yang G, Cui L, Cao Y. A study on a chitosan-gelatin-hyaluronic
acid scaffold as artificial skin in vitro and its tissue engineering applications. J Bio‐
mater Sci Polym Ed 2004;15(1):25-40.
[135] Fu LN, Wang W, Yu LJ, Zhang SM, Yang G. Fabrication of novel cellulose/chitosan
artificial skin composite. Materials Science Forum 2009;610-613:1034-1038.
[136] Yussof SJM, Halim AS, Saad AZM, Jaafar H. Evaluation of the Biocompatibility of a
Bilayer Chitosan Skin Regenerating Template, Human Skin Allograft, and Integra
Implants in Rats. International Scholarly Research Network (ISRN) Materials Science
Volume 2011:1 -7.
[137] Schulz III JT, Tompkins RG, Burke JF. Artificial Skin. Annual Review of Medicine
2000;51:231-244.
[138] Jebahi S, Oudadesse H, Bui XV, Keskes H, Rebai T, Feki A, Feki H. Repair of bone
defect using bioglass-chitosan as a pharmaceutical drug: An experimental study in
an ovariectomised rat model. African Journal of Pharmacy and Pharmacology 2012;
6(16):1276-1287.
[139] Zhang Z, Cui HF. Biodegradability and Biocompatibility Study of Poly(Chitosan-g-
lactic Acid) Scaffolds. Molecules 2012;17:3243-3258.
[140] Li XG, Yang ZY, Zhang AF, Wang TL, Chen WC. Repair of thoracic spinal cord in‐
jury by chitosan tube implantation in adult rats. Biomaterials 2009;30(6):1121–1132.
[141] Wang XH, Yan YN, Xiong Z, Lin F, Wu RD, Zhang RJ, Lu, QP. Preparation and Eval‐
uation of Ammonia Treated Collagen/Chitosan matrices for Liver Tissue Engineer‐
ing. J Biomed Mater Res Part B Appl. Biomater 2005;75B: 91-98.
[142] Wang XH, Li DP, Wang WJ, Feng QL,Cui FZ, Xu YX, Song XH, van der Werf M.
Crosslinked collagen/chitosan matrix for artificial livers, Biomaterials 2003;24(19):
3213-3220.
[143] Wang XH, Cui FZ, Feng QL, Li JC, Zhang YH. Preparation and characterization of
collagen/chitosan matrices as potential biomaterials. J Bioact Compat Polym
2003;18(6):453-467.
[144] Denkbas EB, Seyyal M, Piskin E. Implantable 5-fluorouracil loaded chitosan scaffolds
prepared by wet spinning. Journal of Membrane Science 2000;172(1):33-38.
Advances in Biomaterials Science and Biomedical Applications148
[145] Sun J, Jiang G, Qiu T, Wang Y, Zhang K, Ding F. Injectable chitosan-based hydrogel
for implantable drug delivery: body response and induced variations of structure
and composition. J Biomed Mater Res A. 2010;95(4):1019-1027.
[146] Feng M, Han J, Sun Q, Hou ZQ, Zhang QQ. Preparation and Evaluation of Implanta‐
ble Chitosan-Collagen-Soybean Phosphatidylcholine Film Impregnated with Mito‐
mycin C-PLA- Nanoparticles. 2009. ICBBE 2009. 3rd International Conference on
Bioinformatics and Biomedical Engineering
[147] Sun JL, Jiang GQ, Wang YJ, Ding FX. Thermosensitive chitosan hydrogel for implant‐
able drug delivery: Blending PVA to mitigate body response and promote bioavaila‐
bility. Journal of Applied Polymer Science 2012;125(3):2092-2101.
[148] Rosato DV, Rosato DV; Rosato MV. Plastic product material and process selection
handbook, Elsevier, 2004 p.85, ISBN 978-1-85617-431-2.
[149] Gilding DK; Reed AM. Biodegradable polymers for use in surgery - polyglycolic/
poly (lactic acid) homo- and copolymers: 1. Polymer 1979;20(12):1459–1464.
[150] Cortiella J, Nichols JE, Kojima K, Bonassar LJ, Dargon P, Roy AK, Vacant MP, Niles
JA, Vacanti CA. Tissue-Engineered Lung: An In vivo and In Vitro Comparison of Pol‐
yglycolic Acid and Pluronic F-127 Hydrogel/Somatic Lung Progenitor Cell Con‐
structs to Support Tissue Growth. Tissue Engineering 2006;12(5):1213-1225.
[151] Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Mo‐
tohara S, Uehata H. Initial and 6-month results of biodegradable poly-l-lactic acid
coronary stents in humans. Circulation. 2000;102:399-404.
[152] Bergsma JE, Bos RRM, Rozema F R, Jong W, Boering G. Biocompatibility of intraos‐
seously implanted predegraded poly(lactide): an animal study. Journal of Materials
Science: Materials in Medicine 1996;7(1):1-7.
[153] Aframian DJ, Redman RS, Yamano S, Nikolovski J, Cukierman E, Yamada KM,
Kriete MF, Swaim WD, Mooney DJ, Baum BJ. Tissue compatibility of two biodegrad‐
able tubular scaffolds implanted adjacent to skin or buccal mucosa in mice. Tissue
Eng 2002;8(4):649-659.
[154] Lam KH, Schakenraad JM, Esselbrgge H, Esselbrugge H, Feijen J, Nieuwenhuis P.
The effect of phagocytosis of poly(L-lactic acid) fragments on cellular morphology
and viability. Journal of Biomedical Materials Research 1993;27:1569-1577.
[155] Onuki Y, Bhardwaj U, Papadimitrakopoulos F, Burgess DJ. A review of the biocom‐
patibility of implantable devices: current challenges to overcome foreign body re‐
sponse. J Diabetes Sci Technol. 2008;2(6):1003–1015.
[156] Zoppi RA, Duek EAR, Coraça DC. Barros PP. Preparation and characterization of
poly (L-lactic acid) and poly(ethylene oxide) blends. Materials Research 2001;4(2):
117-125.
Overview on Biocompatibilities of Implantable Biomaterials
http://dx.doi.org/10.5772/53461
149
[157] Nagahama K, Ohya Y, Ouchi T. Synthesis of Star-shaped 8 arms Poly(ethylene gly‐
col)-Poly(L-lactide) Block Copolymer and Physicochemical Properties of Its Solution
Cast Film as Soft Biomaterial. Polymer Journal 2006;38:852–860.
[158] van der Lei B, Bartels HL, Nieuwenhuis P, Wildevuur CR. Microporous, complaint,
biodegradable vascular grafts for the regeneration of the arterial wall in rat abdomi‐
nal aorta. Surgery. 1985 Nov;98(5):955-963.
[159] Middleton J; Tipton A. Synthetic biodegradable polymers as medical devices". Medi‐
cal Plastics and Biomaterials Magazine. 1998 Retrieved 2006-07-04.
[160] Muhonen J, Suuronen R, Oikarinen VJ, Sarkiala E, Happonen R-P. Effect of polygly‐
colic acid (PGA) membrane on bone regeneration around titanium implants inserted
in bone sockets. Journal of Materials Science: Materials in Medicine 1994; 5(1):40-42.
[161] Taylor MS, Daniels AU, Andriano KP, Heller J. Six bioabsorbable polymers: in vitro
acute toxicity of accumulated degradation products. J Appl Biomater 1994;5(2):
151-157.
[162] Anderson JM. Biological responses to materials. Annu Rev Mater Res. 2001;31:81–
110.
[163] van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW,
Holmes DR, Jr, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of
biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circula‐
tion. 1996;94(7):1690–1697.
[164] Venkatraman S, Boey YC. Patent: Implantable article, method of forming same and
method for reducing thrombogenicity. IPC8 Class: AA61F206FI, USPC Class:
623001440, Publication date: 2012-07-12, Patent application number: 20120179242.
[165] Bhardwaj U, Papadimitrakopoulos F, Burgess DJ. A review of the development of a
vehicle for localized and controlled drug delivery for implantable biosensors. J Dia‐
betes Sci Technol. 2008;2(6):1016-1029.
[166] Onuki Y, Bhardwaj U, Burgess PDJ. A Review of the Biocompatibility of Implantable
Devices: Current Challenges to Overcome Foreign Body Response. J Diabetes Sci
Technol 2008;2(6):1003-1015.
[167] Bhardwaj U, Sura R, Papadimitrakopoulos F, Burgess DJ. Controlling acute inflam‐
mation with fast releasing dexamethasone-PLGA microsphere/PVA hydrogel com‐
posites for implantable devices. Journal of Diabetes Science and Technology
2007;1(1):8-17.
[168] Ranganath SH, Yang A, Chan YY, Huang J, Krantz WB, Wang CH. Implantable hy‐
drogel beads entrapping PLGA-paclitaxel microspheres: exploring the effects of
near-zero order drug release for intracranial chemotherapy. AIChE Annual meeting,
Philadelphia, USA, November 2008.
Advances in Biomaterials Science and Biomedical Applications150
[169] Corey JM, Gertz CC, Wang BS, Birrell LK, Johnson SL, Martin DC, Feldman EL. The
design of electrospun PLLA nanofiber scaffolds compatible with serum-free growth
of primary motor and sensory neurons. Acta Biomater 2008;4(4):863-875)
[170] Leach KJ, Takahashi S, Mathiowitz E. Degradation of double-walled polymer micro‐
spheres of PLLA and P(CPP:SA)20 : 80. II. In vivo degradation. Biomaterials
1998;19(21):1981-1988.
[171] Liu JY, LiRen L, Wei Q, Wu JL, Liu S, Wang YJ, Li GY. Toward better bone repair.
2012 Society of Plastics Engineers (SPE).
[172] Woodruff MA, Hutmacher DW. The return of a forgetten polymer – polycaprolac‐
tone in the 21st century. Progress in Polymer Science 2010;35:1217-1256.
[173] Sun HF, Mei L, Song CX, Cui XM, Wang PY. The in vivo degradation, absorption and
excretion of PCL-based implant. Biomaterials 2006;27(9):1735–1740.
[174] Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. Poly- -caprolactone micro‐
spheres and nanospheres: an overview. International Journal of Pharmaceutics
2004;278(1):1-23.
[175] LaVan AD, McGuire T, Langer R. Smallscale systems for in vivo drug delivery. Na‐
ture Biotechnology 2003; 21:1184-1191.
[176] Orosz KE, Gupta S, Hassink M, Abdel-Rahman M, Moldovan L, Davidorf FH, Mol‐
dovan NI. Delivery of antiangiogenic and antioxidant drugs of ophthalmic interest
through a nanoporous inorganic filter. Molecular Vision 2004;10:555-565.
[177] Chung TW, Yang MC, Tseng CC, Sheu SH, Wang SS, Huang YY, Chen SD. Promot‐
ing regeneration of peripheral nerves in-vivo using new PCL-NGF/Tirofiban nerve
conduits. Biomaterials. 2011;32(3):734-743.
[178] Pitt CG, Schinder A. Capronor-A biodegradable delivery system for levonorgestrel.
In: Zatachini GL, editor. Long-acting contraceptive systems. Philadelphia: Harpen
and Row; 1984. p.63–84.
[179] Woodward SC, Brewer PS, Moatamed F, Schindler AK Pitt CG. The intracellular deg‐
radation of poly (epsilon-caprolactone). J Biomed Mater Res 1985;19(4):437–44.
[180] Xia Z, Triffitt JT. A review on macrophage responses to biomaterials. Biomed. Mater
2006;1:R1–R9.
[181] Coury AJ, Slaikeu PC, Cahalan PT, Stokes KB, Hobot CM. Factors and interactions
affecting the performance of polyurethane elastomers in medical devices. J Biomater
Appl 1988 Oct;3(2):130-179.
[182] Coury AJ, Stokes KB, Cahalan PT, Slaikeu PC. Biostability considerations for im‐
plantable polyurethanes. Life Support Syst 1987;5(1):25-39.
[183] Maisel WH. Increased failure rate of a polyurethane implantable cardioverter defib‐
rillator lead. Pacing Clin Electrophysiol. 2002;25(6):877-878.
Overview on Biocompatibilities of Implantable Biomaterials
http://dx.doi.org/10.5772/53461
151
[184] Hauser RG, Cannom D, Hayes DL, Parsonnet V, Hayes J, Ratliff N 3rd, Tyers GF, Ep‐
stein AE, Vlay SC, Furman S, Gross J. Long-term structural failure of coaxial polyur‐
ethane implantable cardioverter defibrillator leads. Pacing Clin Electrophysiol.
2002;25(6):879-882.
[185] Stokes KB, Church T. Ten-year experience with implanted polyurethane lead insula‐
tion. Pacing Clin Electrophysiol. 1986;;9(6 Pt 2):1160-1165.
[186] Santerre JP, Woodhouse K, Laroche G, Labow RS. Understanding the biodegradation
of polyurethanes: From classical implants to tissue engineering materials. Biomateri‐
als 2005;26(35):7457-7470.
[187] Wang Y. Patent: Implantable Medical Devices Fabricated From Polyurethanes With
Grafted Radiopaque Groups. IPC8 Class: AA61F282FI, USPC Class: 623 134, Class
name: Prosthesis (i.e., artificial body members), parts thereof, or aids and accessories
therefor arterial prosthesis (i.e., blood vessel) having marker (e.g., color, radiopaque,
etc.), Publication date: 2009-10-15, Patent application number: 20090259297
[188] Stachelek SJ, Alferiev I, Connolly JM, Sacks M, Hebbel RP, Bianco R, Levy RJ. Choles‐
terol-modified polyurethane valve cusps demonstrate blood outgrowth endothelial
cell adhesion post-seeding in vitro and in vivo. Ann Thorac Surg. 2006 Jan;81(1):47-55.
[189] Ghanbari H, Viatge H, Kidane AG, Burriesci G, Tavakoli M, Seifalian AM. Polymeri‐
ca heart valves: new materials, emerging hopes. Trends in Biotechnology 2009;27(6):
359-367.
[190] Gwendolyn M.R. Wetzels, Leo H. Koole. Photoimmobilisation of poly(N-vinylpyrro‐
lidinone) as a means to improve haemocompatibility of polyurethane biomaterials.
Biomaterials 1999;20(20):1879}-1887.
[191] Staniszewska-Kuś J, Paluch D, Krzemień-Dabrowska A, Zywicka B, Solski L.Tissue
reaction to implanted polyurethane designed for parts of the artificial heart. Polym
Med. 1995;25(3-4):3-18.
[192] Stachelek SJ, Alferiev I, Choi H, Chan CW, Zubiate B, Sacks M, Composto R, Chen I-
W, Levy R. Prevention of oxidative degradation of polyurethane by covalent attach‐
ment of di-tert-butylphenol residues. J Biomed Mater Res A. 2006;78(4):653-661).
[193] Stachelek SJ, Alferiev I, Connolly JM, Sacks M, Hebbel RP, Bianco R, Levy RJ. Choles‐
terol-modified polyurethane valve cusps demonstrate blood outgrowth endothelial
cell adhesion post-seeding in vitro and in vivo Ann Thorac Surg. 2006 Jan; 81(1):47-55.
[194] Alferiev I, Stachelek SJ, Lu ZB, Fu AL, Tiffany L. Sellaro TL, Jeanne M. Connolly JM,
Richard W. Bianco RW, Michael S. Sacks MS, Robert J. Levy RJ. Prevention of polyur‐
ethane valve cusp calcification with covalently attached bisphosphonate diethylami‐
no moieties. J Biomed Mater Res A. 2003; 66(2):385-395.
[195] Chris Smith. Implantable PU developer wins heart valve patent. Time:2009-08-03.
Advances in Biomaterials Science and Biomedical Applications152
[196] Yan YN, Wang XH, Yin DZ, Zhang RJ. A new polyurethane/heparin vascular graft
for small-caliber vein repair. J Bioact Compat Polym 2007;22(3):323-341.
[197] Yin DZ, Wang XH, Yan YN, Zhang RJ. Preliminary studies on peripheral nerve re‐
generation using a new polyurethane conduit. J Bioact Compat Polym 2007;22(2):
143-159.
[198] Fluorine and health:molecular imaging, biomedical materials and pharmaceuticals.
Edited by Alain Tressaud and Günter Haufe. Elsevier, UK
[199] Williams MR, Mikulin T, Lemberger J, Hopkinson BR, Makin GS. Five year experi‐
ence using PTFE vascular grafts for lower limb ischaemia. Ann R Coll Surg Engl.
1985; 67(3):152–155.
[200] von Recum AF, Imamura H, Freed PS, Kantrowitz A, Chen ST, Ekstrom ME, Baech‐
ler CA, Barnhart MI. Biocompatibility tests of components of an implantable cardiac
assist device. J Biomed Mater Res. 1978 Sep;12(5):743-765.
[201] Głowiński S, Worowski K. Local activation of blood coagulation by polyester pros‐
theses implanted into defects of the abdominal aorta of dogs. Polim Med 1977;7(4):
241-243.
[202] Renwick SB. Silicone breast implants: implications for society and surgeons. Med J
Aust 1996 Sep 16;165(6):338-341.
[203] Daniels AU. Silicone breast implant materials. Swiss Med Wkly. 2012;142:doi:
10.4414/smw.2012.13614.
[204] Dewan PA, Condron SK, Morreau PN, Byard RW, Terlet J. Plastic migration from im‐
planted central venous access devices. Arch Dis Child 1999;81:71–72.
[205] Pavlov St, Guidoin R, Marinov G. Histological organization of the capsulae formed
around implanted silicone breast prostheses. Acta Morphologica et Anthropologica
01/2004; 9:50-57.
[206] Roach P, Eglin D, Rohde K, Perry CC. Modern biomaterials: a review—bulk proper‐
ties and implications of surface modifications. Journal of Materials Science: Materials
in Medicine 2007;Volume 18, Number 7 , 1263-1277.
[207] Kim D-H, Kim Y-S, Amsden KJ, Panilaitis B, Kaplan DL, Omenetto FG, Zakin MR,
Rogers JA. Silicon electronics on silk as a path to bioresorbable, implantable devices.
Appl Hys Lett 2009;95:133701.
[208] Stead RJ, Davidson TI, Duncan FR, Hodson ME, Batien JC. Use of a totally implanta‐
ble system for venous access in cystic fibrosis. Thorax 1987;42:149-150.
[209] Guo K, Pei WH, Li XQ, Gui Q, Tang RY, Liu J, Chen HD. Fabrication and characteri‐
zation of implantable silicon neural probe with microfluidic channels. Science China
Technological Sciences January 2012;55 No(1): 1–5.
Overview on Biocompatibilities of Implantable Biomaterials
http://dx.doi.org/10.5772/53461
153
[210] Danckwerts M, Fassihi A. Implantable Controlled Release Drug Delivery Systems: A
Review. 1991;17(11):1465-1502.
[211] Shakhashiri BZ. Chemical of the Week: Aluminum. SciFun.org. University of Wis‐
consin. http://scifun.chem.wisc.edu/chemweek/PDF/Aluminum.pdf. Retrieved
2012-03-04 (17 March 2008).
[212] Takami Y, Yamane S, Makinouchi K, Niimi Y, Sueoka A, Nosé Y. Evaluation of plate‐
let adhesion and activation on materials for an implantable centrifugal blood pump
1. Artif Organs 1998;;22(9):753-758.
[213] Polmear IJ. Light Alloys, Arnold, 1995.
[214] Tseung ACC, King WJ, Wan BYC. An encapsulated, implantable metal-oxygen cell as
a long-term power source for medical and biological applications. Medical and Bio‐
logical Engineering and Computing 1971;9(3):175-184.
[215] Stieglitz T. Flexible biomedical microdevices with double-sided electrode arrange‐
ments for neural applications. Sensors and Actuators A 2001;90:202-211.
[216] Jiang GQ, Mishler D, Davis R, Mobley JP, Schulman JH. Zirconia to Ti-6Al-4V braze
joint for implantable biomedical device. J Biomed Mater Res Part B: Appl Biomater
2005;72B: 316–321.
[217] Dowling RD, Park SJ, Pagani FD, Mohr F-W. HeartMate VE LVAS design enhance‐
ments and its impact on device reliability. European Journal of Cardio-Thoracic Sur‐
gery 2004; 25(6):958–963.
[218] Takami Y, Yamane S, Makinouchi K, Niimi Y, Sueoka A, Nosé Y. Evaluation of plate‐
let adhesion and activation on materials for an implantable centrifugal blood pump.
Artif Organs 1998;22(9):753-758.
[219] Spiliopoulos K, Giamouzis G, Karayannis G, Karangelis D, Koutsias S, Kalogeropou‐
los A, Georgiopoulou V, Skoularigis J, Butler J, Triposkiadis F. Current Status of Me‐
chanical Circulatory Support: A Systematic Review. Cardiology Research and
Practice 2012, Article ID 574198, 12 pages, doi:10.1155/2012/574198.
[220] Myllymaa S. Novel micro- and nano-technological approaches for improving the
performance of implantable biomedical devices. Publications of the University of
Eastern Finland. Dissertations in Forestry and Natural Sciences. University of East‐
ern Finland. P122.
[221] Olga L; Péter B; George KS; Jósef B. Porous hydroxyapatite and aluminium-oxide ce‐
ramic orbital implant evaluation using CBCT scanning: a method for in vivo porous
structure evaluation and monitoring. International Journal of Biomaterials 2012; 1-9:
1687-8787.
[222] Mitsuo A, Aizawa T. Thermal oxidation and characterization for surface layers of Al
implanted TiN films. Ion Implantation Technology Proceedings, 1988 International
Conference on IEEE. Date of Conference: Dec 1999;2:865–868.
Advances in Biomaterials Science and Biomedical Applications154
[223] Sedrakyan A, Normand ST, Dabic S, Jacobs S, Graves S, Marinac-Dabic D. Compara‐
tive assessment of implantable hip devices with different bearing surfaces: systemat‐
ic appraisal of evidence. BMJ 2011;343:d7434-7446.
[224] Defibrillator Risks eHow.com http://www.ehow.com/facts_7438880_defibrillator-
risks.html#ixzz23258fVn4.
[225] Thamaraiselvi TV, Rajeswari S. Biological evaluation of bioceramic materials - a re‐
view. Trends Biomater Artif Organs 2004;18(1);9-17.
[226] Patel NR, Gohil PP. A Review on biomaterials: scope, applications & human anato‐
my significance. International Journal of Emerging Technology and Advanced Engi‐
neering 2012; 2(4), 2250-2259.
Overview on Biocompatibilities of Implantable Biomaterials
http://dx.doi.org/10.5772/53461
155

